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Abstract 
 Candida bracarensis is a rare Candida species, which was recently discovered during an 
epidemiological study of candidiasis performed in Portugal. Initially, C. bracarensis was identified as 
C. glabrata, but detailed analyses showed differences between both species. However, there is still 
little information about C. bracarensis and, for that reason, this dissertation had the general aim to 
study three strains of the that species (NCYC 3133, CNM-CL-7030 and 153 MT) mainly in terms of its 
virulence factors and to compare them with C. glabrata ATCC 2001 and C. albicans ATCC 90028. 
 The first objective was to characterize the three strains of C. bracarensis, concerning its 
colony and cell morphology and its growth kinetics. The results showed that, on CHROMagar, all 
strains presented white colonies, unlike C. albicans and C. glabrata. It was also verified that C. 
bracarensis species formed elliptic or oval cells, with an intermediate size comparatively to the other 
studied species, and that were unable to produce hyphae or pseudohyphae. In the growth kinetics, all 
species presented similar behaviours between them, but different specific growth rates. 
 In addition to filamentous structures, other virulence factors of C. bracarensis were studied. 
The ability of each strain to adhere and form biofilms was assessed and, in this sequence, it was 
showed that C. bracarensis adhered in higher extension, in RPMI, and that its biofilms presented the 
lowest total biomass values. Additionally, the biofilm matrix composition was analysed, but few 
differences were detected between the studied species. Hydrolytic enzymes secretion was also 
assessed by growing the Candida strains on agar medium supplemented with BSA (proteases), egg 
(phospholipases) or blood sheep (haemolysins). C. bracarensis NCYC 3133 was able to secrete 
proteases, like C. albicans, but unlike C. glabrata. In addition, all C. bracarensis strains were able to 
produce haemolysins, but not phospholipases. 
 Lastly, the antifungal resistance of C. bracarensis in planktonic cells and in biofilms (pre-
formed and during its formation) was analysed. In both situations, strains NCYC 3133 and 153 MT 
were the most and least resistant species to amphotericin B, respectively. In contrast, all C. 
bracarensis strains showed high susceptibility to fluconazole, mainly in terms of planktonic cells. The 
effect of these antifungal agents in the enzymatic activity of C. bracarensis was also evaluated. Both 
agents caused a significant increase in the proteolytic activity, but in different Candida species. 
 In conclusion, this study clarified some significant differences between C. bracarensis and C. 
glabrata, which were initially mistakenly, particularly concerning differences found in virulence traits 
and antifungal resistance. 
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Resumo 
 Candida bracarensis é uma espécie rara de Candida, que foi descoberta recentemente num 
estudo epidemiológico realizado em Portugal. Inicialmente, foi identificada como C. glabrata, mas 
análises detalhadas mostraram diferenças entre elas. No entanto, ainda há pouca informação sobre 
C. bracarensis e, por essa razão, esta dissertação teve como objetivo geral estudar três estirpes desta 
espécie (NCYC 3133, CNM-CL-7030 e 153 MT), principalmente em termos dos seus fatores de 
virulência, e compará-las com a C. glabrata ATCC 2001 e C. albicans ATCC 90028. 
 O primeiro objetivo foi caracterizar as três estirpes de C. bracarensis, no que se refere à sua 
morfologia de colónia e celular e à sua cinética de crescimento. Os resultados mostraram que, em 
CHROMagar, todas as estirpes apresentaram colónias brancas, ao contrário de C. albicans e C. 
glabrata. Verificou-se também que as espécies de C. bracarensis formaram células elípticas ou ovais, 
com um tamanho intermédio comparativamente às outras espécies estudadas, e que não foram 
capazes de produzir hifas ou pseudohifas. Na cinética de crescimento, todas as espécies 
apresentaram comportamentos semelhantes, mas diferentes taxas de crescimento específico. 
 Numa segunda fase, mediu-se a capacidade de cada estirpe para aderir e formar biofilmes 
e, nesta sequência, mostrou-se que C. bracarensis aderiu em maior extensão em RPMI, e que os 
seus biofilmes apresentaram os valores de biomassa total mais baixos. Adicionalmente, analisou-se a 
composição da matriz de biofilme, mas poucas diferenças foram detetadas entre as espécies. A 
secreção de enzimas hidrolíticas também foi medida por crescimento em meio agar suplementado 
com BSA (proteases), ovo (fosfolipases) ou sangue de carneiro (hemolisinas). C. bracarensis NCYC 
3133 foi capaz de segregar proteases, como C. albicans, contrariamente à C. glabrata. Além disso, 
todas as estirpes de C. bracarensis foram capazes de produzir hemolisinas, mas não fosfolipases. 
 Por último, analisou-se a resistência antifúngica da C. bracarensis em células planctónicas e 
em biofilmes (pré-formados e durante a sua formação). Em ambas as situações, as estirpes NCYC 
3133 e 153 MT foram as espécies mais e menos resistentes à anfotericina B, respetivamente. Em 
contraste, todas as estirpes de C. bracarensis mostraram alta suscetibilidade ao fluconazol, 
sobretudo em termos de células planctónicas. O efeito destes agentes antifúngicos na atividade 
enzimática de C. bracarensis também foi avaliado. Ambos os agentes causaram um aumento 
significativo na atividade proteolítica, mas em diferentes espécies de Candida. 
 Em conclusão, este estudo clarificou algumas diferenças significativas entre C. bracarensis e 
C. glabrata, que inicialmente eram confundidas, nomeadamente no que diz respeito à sua virulência 
e resistência antifúngica. 
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| General introduction
General introduction 
Chapter 1 | 3 
1.1. Contextualization and aims 
This dissertation focuses on a study carried out concerning a rare and relatively recent 
Candida species – Candida bracarensis (1). Candida is a type of yeast that causes various infections 
in humans and with different infection profiles in the different regions of the world (2). The incidence 
of these infections has significantly increased in last two decades, particularly within health units. The 
major consequences associated to this situation are morbidity and mortality in hospitalized patients 
(3). 
The increase of the number of infections acquired in the health units, commonly designated 
by nosocomial infections, can be attributed to several factors. Recent developments in surgical 
interventions, the increase of the number of immunodeficient patients (such as cancer patients and 
patients hospitalized in intensive care or postsurgical units) and the increase of the 
antibiotics/antifungal resistance are some these factors (4, 5).  
Concerning to antifungal resistance, it is important to note that this phenomena is considered 
a big threat to human health (6). It is caused mostly by the intensive use of antifungal/antibiotics 
(circa 100,000-200,000 tonnes per annum worldwide, according to estimate made in 2002), 
originating a reduction in the efficiency of therapies to the infections treatment and a increase of the 
complications (7). 
In this context, biomedical engineers play an important role. They gather strategies to prevent 
these infections, such as the establishment of a set of standards of hygiene and sterilization and the 
development of materials less liable to the emergence of pathogenic microorganisms. They should 
also sensitize health professionals to the use of these materials and investigate new therapies in the 
treatment of infections, taking into account the resistance mechanisms that have already been 
assumed by several pathogenic strains. 
Therefore, the aims of this project are the study of general characteristics (Chapter 2) and 
potential virulence factors (Chapter 3) of the three Candida bracarensis strains – NCYC 3133, CNM-
CL-7030 and 153 MT – and the analysis of susceptibility of these three strains to two types of 
antifungal agents – amphotericin B and fluconazole – on both planktonic and sessile cells (Chapter 
4). The results obtained from the three Candida bracarensis strains will be also compared with 
reference strains of Candida albicans and Candida glabrata. 
  
General introduction 
4 | Chapter 1 
1.2. Candida species 
From all the pathogenic fungi, Candida species are the most common, mainly in human 
infections (5). 
The genus Candida comprises about 200 species, where Candida albicans strain is the best 
known and the most prevalent, in normal and disease conditions (1, 8). In a study conducted by 
Calderone et al. (9), C. albicans was detected in 80% of isolates from human candidiasis. 
Nevertheless, in the last two decades, and thanks to the improvements in the diagnostic methods 
and the emergence of molecular genetics techniques, new Candida species have been reported in 
human fungal infections – Non-Candida albicans Candida (NCAC) species, specifically Candida 
tropicalis, Candida glabrata, Candida parapsilosis (5, 10). In Table 1.1, it is possible to find more 
information about the most frequent Candida species. 
 
Table 1.1 - Frequency, virulence and clinical associations of some Candida species (11) 
Species Frequency Virulence Clinical associations 
C. albicans 42% - 65% High Most common in all settings 
C. tropicalis 11% - 25% High Cancer 
C. glabrata 7% - 15% Low Cancer 
C. parapsilosis 7% - 18% Variable Plastic devices, hyperalimentation 
C. krusei 1% - 4% Low Cancer 
C. lusitaniae 1% - 2% Low Cancer 
 
1.2.1. Discovery 
In 1665, Pepys reported the first type of candidiasis, a case of “thrush”. But, there have 
never been references to the relationship between the pathogen and this disease until 1846. In that 
year, and through a scientific approach to study thrush, Berg proved that this disease was caused by 
a fungus. After this discovery, other authors did interesting observations: in 1849, in addition to the 
oral infections, Wilkinson observed also the appearance of the aphthae in the sexual organs, caused 
probably by dimorphic fungus and, in 1862 Mayer reported six cases of vaginal thrush. Other forms 
of candidiasis were reported, including cutaneous and systemic disease (9). 
Nevertheless, the identification of the fungus responsible for the thrush was not easy. 
Langenbeck was the first to observe a fungus associated with the thrush, but the identification of this 
organism was not correct. Later, the organism isolated by Langenbeck was classified as a species of 
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Sporotrichum by Gruby, in 1842, and reclassified as Oidium albicans by Robin, in 1847. Other 
incorrect identifications, such as the species of Monilia, were also proposed (9). 
 However, in 1923, Berkhout and collaborators concluded that the fungus responsible for 
thrush lesions did not match Monilia species. Then, a new generic name was indicated by Berkout: 
Candida, a name derived from toga candida, a Latin phrase used by candidates, for the Roman 
Senate, to classify a white robe worn. In this sequence, in 1954, the binomial Candida albicans was 
officially approved as the nomen conservandum in the Eighth Botanical Congress (9). 
Since then, further taxonomic, biochemical and microscopic studies about Candida albicans 
have been conducted. In the last 50 years, new study methodologies of Candida have been adopted, 
mainly those related to molecular biology. The appearance of new identification techniques have also 
contributed to the emergence of new species of Candida (NCAC species) (9, 12). Currently, there are 
approximately 200 known Candida species that are involved in human infection. In Table 1.2, it is 
possible to see some common, less common and rare species of genus Candida known until this 
moment (1). 
 
Table 1.2 - Candida species involved in human infection (1) 
Commom species Less commom species Rare species 
Candida albicans 
Candida glabrata 
Candida tropicalis 
Candida parapsilosis 
Candida krusei 
Candida guilliermondii 
Candida lusitaniae 
Candida kefyr 
Candida dubliniensis 
Candida famata 
Candida inconspicua 
Candida lipolytica 
Candida metapsilosis 
Candida norvegensis 
Candida orthopsilosis 
Candida pelliculosa 
Candida rugosa 
Candida zeylanoides 
Candida blankii 
Candida bracarensis 
Candida catenulate 
Candida chiropterorum 
Candida ciferri 
Candida eremophila 
Candida fabianii 
Candida fermentati 
Candida freyschussii 
Candida haemulonii 
Candida intermedia 
Candida lambica 
Candida magnoliae 
Candida membranaefaciens 
Candida nivariensis 
Candida palmioleophila 
Candida pararugosa 
Candida pseudohaemulonii 
Candida pseudorugosa 
Candida pintolopesii 
Candida pulcherrima 
Candida thermophila 
Candida utilis 
Candida valida 
Candida viswanathii 
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1.2.2. Phenotypic characteristics 
The genus Candida corresponds to a heterogeneous group of yeasts (13). The colonies of 
these microorganisms, in Sabouraud dextrose agar (SDA) medium, present an oval shape, a cream 
colour and can have a bright, dry, smooth or wrinkled texture. Moreover, in standard conditions, this 
yeast grows as budding cells (blastoconidia), yielding spherical or oval cells (approximately 2-5 × 5-7 
µm) (5). Some Candida species, such as C. albicans and C. dubliniensis, have also the ability to 
produce a filamentous type of growth: true hyphae and/or pseudohyphae (14, 15). 
The difference between hyphae and pseudohyphae is related to the way they are formed 
(Figure 1.1). Pseudohyphae are formed from yeast cells or from hyphae by budding. This new 
structure remains attached to the parent cell and elongates, forming filaments with constrictions and 
without septa (internal cross walls). Regarding to true hyphae, they are formed from yeast cells or 
from hyphae branches. The development of these filaments begins in the outgrowths of the yeast cell 
(germ tubes), followed by an elongation and a branching of these same structures. Septa are also 
created to limit the hyphae of fungi (5, 13). Sometimes, hyphae forms are not visible during yeast 
growth in liquid culture or on an agar surface, which suggests that the formation of these biologic 
structures is triggered by contact with a plastic or metal surface, for example (16). 
 
 
 
 
(a) (b) (c) 
Figure 1.1 - The growth forms of Candida species: growth as yeasts (a), production of true hyphae (b) and pseudohyphae (c). Adapted from (13). 
 
Due to their ability to produce hyphae and/or pseudohyphae, C. albicans and C. dubliniensis 
are considered polymorphic microorganisms (5, 14). On the contrary, C. glabrata is described as non-
polymorphic because it does not produce growth filaments, growing only as blastopore. Interestingly, 
in an initial phase and due to this situation, C. glabrata was classified in the genus Torulopsis. Later, 
in 1978, it was verified that the ability to produce hyphae and/or pseudohyphae was not a decisive 
factor in the distinction of members of the genus Candida. Moreover, other Candida species are able 
to form filaments as C. parapsilosis that can produce pseudohyphae, but no true hyphae and C. 
General introduction 
Chapter 1 | 7 
tropicalis that forms true hyphae and was described, in some cases, as producer of pseudohyphae 
(5). 
Concerning Candida cell wall (Figure 1.2), Chattaway (17) demonstrated that the 
composition of Candida albicans cell wall is practically constant in different media and temperatures. 
In addition, it was shown that the composition of the yeast and hyphal cell walls also does not vary 
qualitatively, but quantitatively for some specific components, such as chitin (18). 
 
 
Figure 1.2 - A section of the C. albicans cell wall by transmission electron microscopy and scheme about the arrangement of the major components of cell 
wall (19). 
 
In fact, the cell wall of Candida is composed by diverse components: lipids, proteins and 
carbohydrates (chitin, glucans and mannan). Lipids are the minor component of the cell wall of fungi 
in general, including C. albicans. Phospholipomannan is perhaps the most important lipid because it 
reacts with antibodies specific to ß-1,2-oligomannosides. Furthermore, it is also possible to find 
proteins in the cell wall that assume important and varied roles, such as the degradation of large 
impermeable molecules facilitating the internalization of nutrients, and the involvement in the 
establishment of the pathogens in the host. Some of these proteins are covalently associated to 
mannose polymers (mannan), forming mannoproteins that constitute the fibrillar outer layer of the 
cell wall. Mannan is an interesting component that confers immunodominant properties to the cell 
and promotes the adherence of the fungus to epithelial cells. Regarding chitin, this is one of the most 
insoluble natural products which, in conjunction with ß-1,3-glucans, belongs to the mannoprotein 
outer layer. Glucans are the most abundant polysaccharides present in the cell wall of Candida, 
which does not have α-glucans, but only ß-glucans (ß-1,3 and ß-1,6 glucans, for example) (19, 20). 
Finally, it is also important to refer that the cell wall of C. albicans has a lower amount of proteins 
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(3.3-3.7%) and mannose (24.3-28.9%), and a larger amount of chitin (4.1-4.3%) and glucans (10-
11.2% [ß-1,3]; 25.1-27.3% [ß-1,6]) than C. glabrata (21). 
The different Candida species can be easily distinguished by other factors: colony color on 
chromogenic agar medium (CHROMagar), yeast size and biochemical and genetic characteristics (5). 
On CHROMagar (Figure 1.3), C. albicans presents blue-green colonies, C. tropicalis dark-blue 
colonies, C. glabrata white or pink-purple colonies, whereas C. parapsilosis has white colonies (13, 
22). Regarding yeasts’ size, and according to Calderone (13), C. albicans cells (4-6 × 6-10 µm) are 
bigger than cells of C. tropicalis (4-8 × 5-11 µm), C. parapsilosis (2.5-4.0 × 2.5-9.0 µm) and C. 
glabrata (1-4 µm). In this sequence, C. glabrata cells are the smallest in comparison with the other 
species already mentioned (12). 
 
 
Figure 1.3 - Colonies of Candida species grown for 48 h on CHROMagar at 37° C: (a) C. albicans; (b) C. glabrata; (c) C. parapsilosis and (d) C. tropicalis. 
Adapted from (22). 
 
In relation to biochemical characteristics of these species, it is important to refer that C. 
albicans has the ability to ferment or assimilate a large group of sugars with the exception of sucrose, 
while the NCAC species ferment and assimilate specific sugars: glucose and trehalose, in the case of 
C. glabrata, and sucrose and maltose, in the case of C. tropicalis, for example. It is also described 
that C. parapsilosis does not have the ability to ferment maltose (5). 
From the genetic point of view, there are also differences between some NCAC species and 
C. albicans. In fact, C. glabrata and C. lusitaniae present a haploid genome, while C. albicans and 
(a) 
 
(b) 
 
(c) 
 
(d) 
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several NCAC species (for example, C. dubliniensis, C. tropicalis and C. parapsilosis) have a diploid 
genome. Moreover, it is also referenced that C. tropicalis presents a higher similarity to C. albicans 
and a lower one to C. glabrata (5, 23). 
 
1.2.3. Pathogenicity and virulence factors 
Virulence factors are all those factors associated to metabolic pathways and that directly 
interact with the host tissue causing damages and infection: the ability to adhere and form biofilm, 
the secretion of hydrolytic enzymes (e.g. proteases, phospholipases and haemolysins) and the ability 
to produce filamentous forms that facilitate the invasion of the host tissue, for example (24, 25). 
Then, the pathogenicity will depend on the several of virulence factors that the microorganism has 
(5). 
Investigations about virulence factors of Candida species have shown that Candida albicans 
is the most pathogenic organism in the Candida group (26, 27) and that it has the highest levels of 
virulence factors (8). 
 
1.2.3.1. Adhesion 
The adhesion of a microorganism to a host tissue and/or medical device surface is the first 
event in Candida infection, giving origin to biofilm formation (10). Adhesion is an essential 
phenomenon because it contributes to the persistence of the pathogen in the host and to the 
establishment of infection (5). However, the adhesion is dependent on several factors such as the cell 
wall proteins, that are recognized by the receptors present on epithelial, endothelial and foreign-body 
surfaces (for example, fibronectin, fibrinogen and vitronectin), and cell surface physicochemical 
properties (28). 
 In the Candida species, there are specialized cell wall proteins in the adhesion process – the 
adhesins. Fungal adhesins (Figure 1.4) present a common three-domain structure: the C-terminal 
part (composed by a glycosylphosphatidylinositol (GPI)-anchor and by addition links to the cell wall), 
the N-terminal part (composed by a carbohydrate or peptide binding domain) and the large middle 
domain (that contains multiple serine- and threonine-rich repeats). These glycoproteins promote the 
interactions of the yeast cells with each other, mammalian host tissues and inert surfaces, mainly in 
biofilm formation (29, 30). 
The genes responsible for encoding the major group of adhesins in C. albicans are members 
of the ALS (agglutinin-like sequence) family genes, but recently other adhesin genes associated to C. 
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albicans have been reported (such as EAP1, INT1 and HWP1 genes) (29, 31). In relation to adhesins 
of C. glabrata, they are encoded by the EPA (epithelial adhesin) genes, where their expression is 
induced by the presence of nicotinic acid (10, 32). There are few studies about Epa proteins, but it is 
already known that Epa1p is a calcium-dependent lectin, whose deletion of EPA1 alone reduces 
adherence in vitro and that EPA6 expression does not happen in vitro, but in vivo during urinary 
infection (10, 33). About the adhesins of other Candida species, there is still little information (5, 10). 
 
 
Figure 1.4 - Representation of interaction between yeast cells mediated by fungal adhesins. Generally, in this process, active confirmation of the adhesins is 
achieved by action of calcium ions (30). 
 
Concerning cell surface physicochemical properties, it is necessary to refer cell surface 
hydrophobicity. Some studies have reported that there is a correlation between adhesion and surface 
hydrophobicity of Candida cells, but there are other studies that show the opposite (5). In 2001, 
Panagoda et al. (34) verified the existence of an association between the initial adhesion of C. 
parapsilosis cells and the hydrophobicity of acrylic surfaces. Nevertheless, in 2007, Camacho et al. 
(35) demonstrated that there was no correlation between adhesion of Candida species to siliconized 
latex catheters and the cell hydrophobicity alone. Another study about adhesion of NCAC species to 
silicone in the presence of urine, developed by Silva et al. (36), also showed that C. glabrata, C. 
parapsilosis and C. tropicalis were hydrophilic, a fact that did not influence the adhesion of these 
strains. They even concluded that zeta potential was not primarily responsible for the adhesion. 
Furthermore, some authors have considered that the extent of surface roughness is an important 
factor in the adhesion of microorganism to surfaces (36). 
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1.2.3.2. Biofilm formation 
Biofilm is the most prevalent growth form of microorganisms and is defined as a community 
of cells attached to a surface and embedded in an extracellular matrix (ECM), that is composed by 
substances produced by microbial cells (37, 38). It is a severe virulence factor of Candida species, 
because it presents a complex and heterogeneous three-dimensional structure that prevents the 
penetration of substances/drugs, which confers antifungal resistance, and attenuates immune 
responses from host beneath cells contained in matrix. This architecture also promotes the influx of 
nutrients, the secretion of waste products and the establishment of microniches, allowing the 
maturation of biofilms (10, 39). 
The formation of these biologic structures (Figure 1.5) can be explained in five stages. 
Initially, yeast cells are adsorbed (i) and adhere (ii) to the surface followed by the formation of the 
basal layers of yeast colonies, the initial formation of hyphae (in the cases where Candida species 
have this ability) and the production of ECM surrounding the cells and hyphae (iii). Finally, it occurs 
the maturation of the biofilm, that results in the association of several microcolonies and emergence 
of water channels that allow circulation of nutrients and other substances (iv), followed by the 
dispersal of cells biofilm (v) (37). However, the formation and the architecture of mature biofilms 
depend on the species, strain, substrate properties (such as medium composition) and growth 
conditions (for example, pH and oxygen) (10, 39).  
 
 
Figure 1.5 - Model of biofilm development in Candida albicans. Adapted from (37). 
 
There are some differences between the biofilms produced by Candida albicans and by 
NCAC species (39). Due to the dimorphism of C. albicans (ability to grow in the yeast form and in the 
hyphae form), its biofilms are distinguished by the presence of two distinct layers (Figure 1.5 (iv)): 
thin (basal yeast layer) and thicker (less compact hyphal layer) (10, 40). It is important to highlight 
that some strains of C. albicans can be described as good biofilm producers (41, 42). In relation to 
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ECM composition of C. albicans biofilms, Al-Fattani et al. (38) showed that this contains a high level 
of carbohydrates (39.6%, including 32.2% glucose) and a low level of proteins (5.0%), hexosamines 
(3.3%), phosphorus (0.5%) and uronic acid (0.1%). 
 Concerning NCAC species biofilms, there are also differences between C. glabrata, C. 
parapsilosis and C. tropicalis, as it can be observed in Table 1.3 (10). In Sabouraud dextrose broth 
(SDB) or another rich culture medium, C. glabrata forms lower biofilms, compared to C. parapsilosis 
and C. tropicalis, but its biofilm structure is more compact (43). As for C. parapsilosis, its biofilm 
structure is thinner, less organized and composed essentially by aggregated blastopores. C. 
parapsilosis has still a greater ability to produce biofilm on materials with plastic surface, such as 
catheters (10). Finally, C. tropicalis is described as a prolific biofilm producer and it has ability to 
produce extensive biofilms in polyvinyl chloride (PVC) catheter and polystyrene surfaces. A dense 
network of yeast cells and hyphae and/or pseudohyphae characterizes its biofilm structure (10, 44). 
  
Table 1.3 - Characteristics of C. glabrata, C. parapsilosis and C. tropicalis biofilm (10) 
Species Biofilm formation Biofilm structure Matrix composition 
C. glabrata Less biofilm growth 
Compact monolayer or 
multilayer 
High level of carbohydrates 
and proteins 
C. parapsilosis Robust biofilm growth 
Discontinuous monolayer 
or multilayer 
High level of carbohydrates 
and low levels of proteins 
C. tropicalis Robust biofilm growth 
Discontinuous compact 
monolayer 
Low level of carbohydrates and 
proteins 
 
The ECM composition of NCAC species biofilms also varies. C. glabrata presents a biofilm 
matrix composed by high quantities of carbohydrates and proteins, while the biofilm matrix of C. 
parapsilosis has high levels of carbohydrates, but low amounts of proteins. Moreover, biofilm matrix of 
C. tropicalis contains high levels of hexosamine – the major component –, low quantities of 
carbohydrates and proteins, phosphorus and uronic acid (10, 38). 
 
1.2.3.3. Enzymes production 
Candida species produces and release hydrolytic enzymes to the environment, such as 
secreted aspartyl proteinases (Saps), phospholipases, and haemolysins. These enzymes promote the 
destruction of host tissues, constituting important virulence factors (5). 
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Secreted aspartyl proteinases 
Saps are enzymes that facilitate invasion of host tissues through the degradation of mucosal 
components (collagen, keratin and mucin) and important immune proteins (antibodies, complements 
and cytokines). Studies have demonstrated that C. albicans, C. parapsilosis and C. tropicalis are good 
producers of Saps (5, 44-46). In C. albicans, ten SAP genes, which act in the adhesion (of this 
species), tissue damage and immune responses evasion of host, encode Saps. It is also necessary to 
refer that there are SAP genes of C. albicans more specific for mucosal (SAP1-3) and systemic (SAP4-
6) infections and that proteinases activity varies with pH (45). In relation to C. parapsilosis, three 
genes have been identified (SAPP1-3), but two of these genes are not characterized. In addition, C. 
tropicalis Saps are encoded by four genes (SAPT1-4), but only Sapt1p is duly characterized. About C. 
glabrata, there is only a study that indicates that this species produces proteinase, but the proteinase 
type is unknown (5). 
 
Phospholipases 
 Phospholipases hydrolyse phospholipids into fatty acids and cause host cell membrane 
damage, facilitating the invasion of host tissues by exposition of receptors to adhesion. The 
production of four types of phospholipases by C. albicans has been reported (phospholipase A, B, C 
and D). Other studies concerning C. albicans phospholipases allowed the detection of the presence of 
extracellular products related only to PLB1 and PLB2 genes. The PLB1 has been indicated as the 
gene that has an important role in the secretion of phospholipase B by C. albicans (45). 
 According to several studies, NCAC species also produce extracellular phospholipases, but in 
lower quantities than C. albicans (5). However, C. tropicalis has been indicated as the producer of 
low levels of extracellular phospholipases (44). Besides, there are few studies about the production of 
these enzymes by C. tropicalis and C. parapsilosis and there are not any investigations concerning C. 
glabrata phospholipase production (5). 
 
Haemolysins 
 Haemolysins are responsible for the degradation of haemoglobin and by extracting the 
elemental iron from host cells. It is through haemoglobin degradation that microorganisms (such as 
Candida species) develop growing in host tissues, because they use this compound as a source of 
iron (5, 47). 
General introduction 
14 | Chapter 1 
 Several authors have reported that C. albicans and some NCAC species produce haemolysins 
after 48 hours of incubation (44, 48, 49). It is known that C. albicans, through iron, produces a 
haemolytic factor that allows the release of haemoglobins by erythrocytes lyses. However, the 
production of haemolysins in vitro by C. glabrata, C. parapsilosis and C. tropicalis causes partial or 
total erythrocyte lyses. Moreover, the HLP (haemolysin like protein) gene has also been indicated as 
responsible for the haemolytic activity of C. glabrata (5, 47). 
 
1.2.3.4. Filamentous growth 
As already mentioned in section 1.2.2., there are some Candida species that produce hyphae 
and/or pseudohyphae. These biologic structures facilitate the invasion of pathogenic microorganism 
in healthy tissue of host and increase resistance to phagocytosis (5). 
In 2006, Jayatilake et al. (8) has shown that C. albicans with no hyphae presented a lower 
ability to invade tissue compared to other Candida species with which presented hyphae. In addition, 
studies developed by Silva et al. (50, 51), about the influence of filamentous forms on host tissue 
invasion, indicated interesting results. They revealed that the filamentous forms of C. tropicalis were 
able to invade a human oral epithelium (Figure 1.6) (50) and that the invasion of C. parapsilosis in 
this same tissue is not related to pseudohyphae formation, contrary to what happens with C. albicans 
and C. tropicalis (51). Relatively to C. glabrata, it has been described as non-invasive in studies of in 
vitro invasion by Candida species, where reconstituted human epithelium was used. This situation 
has been explained by the inability of C. glabrata to generate filamentous forms (10). 
 
 
Figure 1.6 - Confocal laser scanning microscopy (CLSM) image that shows the invasion of C. tropicalis 75 in human oral epithelium, after 24 h of 
incubation. Adapted from (50).  
10 µm 
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1.3. Candida bracarensis 
Candida bracarensis is a rare Candida species, which was discovered recently (1, 4). 
 
1.3.1. Discovery 
In 2004, following an epidemiological study of candidiasis in the north of Portugal, one strain 
of Candida (153 MT) was collected in one of the clinical isolates from a vaginal exudate. This strain 
was initially identified as C. glabrata, but later, some studies showed differences between the strain 
153 MT and C. glabrata (4). 
Moreover, a second strain (NCYC 3133, formerly NCYC D3411) was found in a search for 
similar sequences in the GenBank sequence database. This strain, collected from a blood culture 
from a patient in a United Kingdom hospital, presented a high sequence similarity with the 26S rDNA 
D1/D2 region of 153 MT (only a single nucleotide was different) (4). 
Strains 153 MT and NCYC 3133 were then analysed by standard chemotaxonomic methods 
and by polymerase chain reaction (PCR) fingerprinting with primer T3B, with the purpose of clarifying 
the taxonomic position of new Candida species. Throughout this analysis, it was verified that the two 
isolates presented similar physiological and molecular characteristics with C. glabrata and 
Kluveromyces delphensis (at the present Nakaseomyces delphensis). Though, the level of differences 
between the two isolates and these two last microorganisms was considered large enough for the 
emergence of a new Candida species – Candida bracarensis. Out of curiosity, the choice of the 
species name comes from Bracara Augusta, the roman name of Braga (Portuguese city) where strain 
153 MT was isolated (4). 
 In the sequence of this discovery, new cases of C. bracarensis have been reported. Some 
authors, such as Bishop et al. (52) and Warren et al. (53), have considered the strain 153 MT as 
control in the identification of new cases of C. bracarensis. 
 
1.3.1.1. Cases reported to date 
To author’s best knowledge, there are only few cases of Candida bracarensis reported. In the 
Table 1.4, it is possible to see information about these cases. 
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Table 1.4 - Cases reported of Candida bracarensis 
Publication 
Year 
Isolate [References] Source Region/Country 
2006 153 MT * (4, 54) 
Vaginal exudates from patient with 
candidiasis 
Braga, Portugal 
2006 NCYC 3133** (4, 55) 
Blood culture from patient central 
venous catheter 
United Kingdom 
2008 C. bracarensis HOP-15*** (52) Stool from patient with AIDS USA 
2008 Cagl-78 (52) 
Stool from oncology patient (with 
acute myelogenous leukaemia) 
USA 
2008 Cagl-112 (52) 
Pelvic abscess from patient with 
perforated diverticulitis 
USA 
2008 Cagl-121 (52) 
Throat from oncology patient (with 
anaplastic large-T-cell lymphoma) 
USA 
2008 CNM-CL-7030 (56) 
Catheter exudate of a critically ill 
patient 
Spain 
2009 C. bracarensis no. 1 (57) Sputum USA 
2009 C. bracarensis no. 2 (57) Blood culture USA 
2009 CNM-CL-7326 (56) 
Pleural liquid from a patient who 
underwent thoracic surgery 
Spain 
2009 CNM-CL-7380 (56) 
Blood culture from a patient with a 
haematological disease 
Spain 
2010 
Clinical isolate 1 (53) Blood culture from 
immunocompromised patient 
Canada 
Clinical isolate 2 (53) 
2010 Two isolates (58, 59) Various clinical samples India 
* Equivalent strain designations: NCYC 3397, NCYC D3853T, CECT 12000T, CBS 10154T, NRRL Y-48270T, C. bracarensis type strain (TS). 
** Equivalent strain designation: NCYC D3411. 
*** Equivalent strain designation: NRRL Y-27794. 
 
 As for the isolates mentioned in the Table 1.4, it is necessary to refer that the isolates Cagl-
78, Cagl-112 and Cagl-121 were identified by peptide nucleic acid fluorescence in situ hybridization 
probes and were then confirmed by sequencing of the D1/D2 region (52). In addition, the two 
isolates from Canada were not initially identified as C. glabrata by the API 20C system, unlike what 
happened with other studies. This fact suggests that C. bracarensis has been misidentified as C. 
glabrata (53). Today, commercial identification kits can already easily distinguish these two Candida 
species such as the Glabrata RTT test (Fumouze Diagnostics, Levallois Perret, France) (1). 
 
1.3.2. Characteristics 
Candida bracarensis is a pathogenic and anamorphic yeast (1). The cells of this species have 
a spherical shape (3.0–3.5 µm) or an elliptical one (3.0-4.0 x 4.0-4.5 µm). In Figure 1.7, it is possible 
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to see that the cells in this Candida species may appear singly or grouped. Still in its morphology, it 
was not detected the production of pseudohyphae and true hyphae, under the coverglass in Dalmau 
plate culture on cornmeal agar after 21 days at 25°C, nor the asexual (ballistospores, arthrospores, 
endospores, chlamydospores) and sexual spores (ascospores and teliospores) (4, 54, 55). These 
fungal cells also divide by budding, which is multipolar, and not by fission (54, 55). 
 
 
Figure 1.7 - Morphology of C. bracarensis 153 MT cells grown in YM broth after 3 days at 30°C (Bar, 10 µm). This image was obtained by differential 
interference contrast microscopic (4). 
 
On Yeast malt (YM) agar, C. bracarensis produces cream/pale yellow, shiny, smooth and 
butyrous colonies with an entire margin, whereas on CHROMagar Candida medium (at 37°C), these 
colonies are white (4, 52, 53, 60). Furthermore, in broth medium, this Candida species is not 
flocculent (54, 55). 
As for its fermentation process, this yeast has the ability to ferment glucose and α,α-
trehalose. For this reason, C. bracarensis assimilates some carbohydrates (glucose, sucrose and α,α-
trehalose), glycerol, D-glucono-1,5-lactone and D-gluconate. As a nitrogen source, this Candida specie 
only assimilates the L-lysine (4, 54, 55). 
 
1.3.3. Candida bracarensis versus other species 
As previously mentioned in point 1.3.1., strains 153 MT and NCYC 3133 were characterized 
by Correia et al. (4) in order to clarify its taxonomic position. The study revealed similarities of these 
two isolates with C. glabrata and K. delphensis, similarities that we will now see. 
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 In the PCR fingerprinting with primer T3B, it was detected (Figure 1.8 (a)) that the strains 
153 MT and NCYC 3133 presented similar profiles with one another, but different profiles with C. 
glabrata and K. delphensis (4). 
Through the neighbour-joining method, based in the alignment of 26S rDNA D1/D2 region 
sequences, and PAUP* version 4.0b8 software package, it was possible to build the phylogenetic tree 
represented in Figure 1.8 (b). The sequence similarity values were also estimated and it was verified 
that between C. glabrata and K. delphensis, there are 92% of similarities and that strain 153 MT is 
94.8% similar to C. glabrata and 93.8% with K. delphensis. However, this phylogenetic analysis was 
also enlarged to the comparison between entire ribosomal internal transcribed spacer (ITS) region 
sequences. In this case, strain 153 MT revealed 65% similarities with C. glabrata, 68% with K. 
delphensis and 96.9% with NCYC 3133 (4). 
 
 
 
 
(a)  (b) 
Figure 1.8 - (a) PCR profiles (with primer T3B) obtained to C. glabrata CBS 138T (1); Kluyveromyces delphensis PYCC 2899 (2); strain 153 MT (3) and strain 
NCYC 3133 (4). (b) Phylogenetic tree derived from the alignment of 26S rDNA D1/D2 region sequences. It is represented only bootsrap percentages (1000 
replicates) of 50% or greater. Bar, 1% nucleotide sequence divergence (4). 
 
Another factor that distinguishes C. bracarensis from C. glabrata and K. delphensis is 
compounds assimilation. While C. bracarensis assimilates L-lysine as a sole nitrogen source, C. 
glabrata does not utilize this compound or utilizes it in small amounts. Concerning the K. delphensis, 
the distinction with C. bracarensis is also easy because strains 153 MT and NCYC 3133 assimilate 
both L-lysine and α,α-trehalose, to ferment α,α-trehalose, and do not assimilate ethanol (4). 
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1.4. Antifungal resistance 
As already mentioned, infections by Candida species have increased significantly, causing 
high morbidity and mortality in immunocompromised patients. In the origin of this phenomenon is 
the increase of antifungal resistance (3, 61, 62). Several factors can explain the former situation: the 
increase of intrinsically resistant species, the accumulation of mutations that cause resistance, the 
swap of mobile resistance components and the excessive use of drugs to treat infections. So, the 
understanding of mechanisms associated to antifungal resistance is indispensable to counter actual 
trend (6). 
Antifungal resistance can be characterized by microbiologic or clinical resistance, or by both. 
Concerning microbiologic resistance, this happens when the growth of the pathogen is inhibited by a 
higher dosage of antifungal concentration connected/related to the susceptibility breakpoint for that 
same microorganism (61, 63). This resistance can be intrinsic (primary) or acquired (secondary). The 
first is found in fungi without prior exposure to the antifungal agent, while acquired resistance occurs 
in the strains, previously classified as susceptible, after exposure to the drug. Generally, in this last 
case, the resistance appears associated to altered gene expression (61). 
When there is a failure in the administration of an antifungal agent (with in vitro activity 
against the pathogen), this resistance is considered of clinical origin. This failure is due to a 
combination of several factors originating from the administered drug, host and type of pathogen 
(61). 
Resistance is only classified as microbiologic and clinical when normal concentrations of 
antifungal do not inhibit the pathogens and when the minimum inhibitory concentrations (MICs) are 
situated in an interval propitious to the development of the resistance mechanisms or where there are 
not studies about the clinical success of antifungal agent against the respective microorganism (63). 
Regarding the consequences of antifungal resistance, it is noteworthy the economic problems 
and the elevated MICs, associated to the increase of invasive fungal infections in high-risk patients 
during the antifungal therapy and prophylaxis (7, 63). It is also important to refer that the level of 
severity of consequences depends on the biology and population size of the pathogen, the antifungal 
properties and the resistance mechanisms acquired by the respective strain (6). 
 
1.4.1. Antifungal susceptibility testing 
The techniques for in vitro antifungal susceptibility testing are now standardized (63). 
Nowadays, there are guidelines created by the Clinical and Laboratory Standards Institute (CLSI), for 
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susceptibility testing of yeasts and filamentous fungi, and by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), for testing Candida and Aspergillus species (61). 
The CLSI, apart from the broth microdilution (BMD) testing, has presented other MIC 
methods for antifungal susceptibility testing such as disk diffusion testing for yeasts. This last method 
is more convenient, simpler, more economical and more suited for water-soluble antifungals (such as 
fluconazole and voriconazole) than the BMD (63). 
Before proceeding, it is important to clarify the MIC concept: it is the lowest drug 
concentration for which it is verified a significant reduction (50% or 90%) of growth of a 
microorganism. This value is quantified from the measuring of a strain growth in contact with a range 
of drug concentrations, during a period time and according to a specific standard (64). 
However, MICs values do not always reflect the clinical response to antifungal therapy, 
because there are always complex interactions between the pathogen and host that are 
unquantifiable (64). In fact, in 90% of cases, the antifungal therapy is successful against infections 
caused by susceptible strains, while the therapy used to treat infections caused by resistant strains, it 
has only success in 60% of cases. Furthermore, MICs are not always considered the best measure of 
resistance because, in fungal infections exposed to the antifungal agent, it has been detected some 
activity against conidia and not against filamentous structures such as hyphae (61). 
 
1.4.2. Resistance mechanisms to antifungal agents 
The main antifungal agents currently used are polyenes (ergosterol disruptors), azoles (fungal 
ergosterol synthesis inhibitors), flucytosine (nucleic acid synthesis inhibitor) and echinocandins 
(glucan synthesis inhibitors). These antifungals are classified in function of their targets in the 
antifungal therapy (Figure 1.9) (65). 
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Figure 1.9 - Targets for antifungal therapy. Adapted from (66). 
 
1.4.2.1. Polyenes 
Polyenes are fungicidal agents and have the broadest spectrum of action against fungi 
species. These agents act within fungal membrane where, in conjunction with ergosterol (the main 
sterol present in the fungal cell membranes), form porin channels. In turn, these channels increase 
membrane permeability, leading to leakage of cellular constituents and, consequently, loss of cellular 
function and cell death (61, 65, 67). 
 Nystatin and amphotericin B (Figure 1.10) are examples of polyenes isolated from 
Streptomyces species. The first drug, discovered in 1950, is recommended to the treatment of 
oropharyngeal candidiasis, despite not being absorbable after oral administration. In what concerns 
amphotericin B, this antifungal is used in cases of serious and invasive Candida infections and 
against Blastomyces dermatitidis, Coccidioides immitis, Cryptococcus neoformans, Histoplasma 
capsulatum, Paracoccidiodes brasiliensis and Sporotrichium species (5, 65). However, amphotericin 
B has some disadvantages such as toxicity to mammalian cells, since it causes nephrotoxicity, and 
low blood potassium levels (65, 68). 
 
 
Figure 1.10 - Chemical structure of amphotericin B. Adapted from (68). 
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Nevertheless, recently, some resistance to amphotericin B has been described. The 
resistance to this polyene is detected for a MIC superior or equal to 1 µg/ml. Various causes can 
explain the resistance to polyenes, namely, mutation in the ERG3 (the gene responsible for ergosterol 
biosynthesis), which leads to formation and to accumulation of other sterols in the plasmatic 
membrane of the fungal cell; and mutation in ERG11 and in ERG6 (genes that produce lanosterol 
14α-demethylase and that intervene in normal membrane function, respectively) (5, 61, 69, 70). 
Either the increase catalase activity or the decrease of susceptibility to oxidative damage also 
contribute to resistance to amphotericin B (61). 
 
1.4.2.2. Azoles 
Azoles constitute the largest group of the antifungals class used clinically and, generally, 
present a fungistatic activity against Candida species (5, 71). The main function of these agents is to 
block the ergosterol biosynthesis pathway, through the inhibition of lanosterol 14α-demethylase (an 
enzyme responsible for converting lanosterol to ergosterol) and, in some fungi species, of the 
inhibition of ∆22-desaturase step (68, 69). In this sequence, ergosterol is depleted and the fungal 
membrane structure undergoes some changes, in terms of permeability and fluidity, as well as its 
functions (for example, the non-production of the enzymes necessary for cell wall synthesis). Thus, all 
these phenomena lead to the inhibition of fungal growth (63, 68). 
Fluconazole (Figure 1.11) and itraconazole are the main azoles clinically used, but there are 
others such as voriconazole and posoconazole, for example. The fluconazole is a drug that emerged 
in 1994, to treat vaginal candidiasis, and currently, it is extensively used in the treatment of 
superficial and invasive infections caused by various Candida species, such as C. albicans, C. 
parapsilosis and C. tropicalis. Itraconazole is another azole that has anti-Aspergillus activity and that 
can be administered in patients infected with Candida species susceptible or resistant to fluconazole, 
except for C. glabrata.  However, fluconazole is better than itraconazole, specifically in the treatment 
of acute cryptococcal infection and cryptococcal meningitis, in patients with Acquired Immune 
Deficiency Syndrome (AIDS). In relation to voriconazole, it has fungicidal activity against Candida 
(including C. albicans and C. glabrata), Aspergillus and Fusarium species. The patients treated with 
voriconazole can present some secondary effects such as hallucinations, encephalopathy, skin rash 
among others. Finally, there is posoconazole, which emerged in 2006, to treat invasive Aspergillus 
and Candida infections. Posoconazole presents fungistatic activity mainly against some NCAC species 
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and a molecular structure similar to itraconazole. The main secondary effects of this last antifungal 
are gastrointestinal (5, 65). 
 
 
Figure 1.11 - Chemical structure of fluconazole. Adapted from (68). 
 
 Concerning resistance to azoles, there are four main mechanisms described to Candida 
species. In each resistant strain, it is possible to find more than one active mechanism. The first is 
associated with activation of two types of efflux pumps, encoded by either CDR or MDR genes (two 
genes that belong to gene families of transporters). This activation leads to decreased antifungal 
concentration in the site of action, within the fungal cell, therefore causing the resistance. Studies 
have proven the involvement of the CDR or MDR genes in resistance of C. albicans (CDR1, CDR2, 
and MDR1), C. glabrata (CgCDR1 and CgCDR2) and C. dubliniensis (CdCDR1 and CdMDR1) to 
azoles. The second mechanism involves point mutations in ERG11 (gene that encodes for the target 
enzyme), which decreases the binding capacity between azoles and target enzymes. However, this 
situation can be aggravated if there is an overexpression and upregulation of the altered target 
enzymes – the third mechanism. In this case, the azole agents are overwhelmed and, subsequently, 
the therapeutic drug concentrations are insufficient to treat the infected patient. Nevertheless, it is 
important to highlight that this mechanism is not yet considered the most responsible for resistance 
to azoles. Finally, the fourth mechanism is related to the development of bypass pathways, caused by 
mutations in ERG3 gene. This altered gene prevents the formation of 14α-methyl-3,6-diol, a toxic 
component necessary to death of the cell, and, subsequently, it originates functional membranes, 
denies the effects of azoles and inhibits the fungal cells growth (61, 63, 69). 
 
1.4.2.3. 5-Flucytosine 
 5-Flucytosine is an antifungal agent that inhibits DNA and protein synthesis. This drug, 
initially developed as an anticancer agent, is internalised by cytosine permease and, once inside the 
fungal cells, it is converted into 5-fluorouracil, by a cytosine deaminase, and then into 5-fluorouridylic 
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acid, by UMP pyrophosphorylase. Afterwards, 5-fluorouridylic acid is phosphorylated and incorporated 
into RNA molecules, affecting both the DNA and protein synthesis (5, 65). 
The spectrum of activity of flucytosine (Figure 1.12) is restricted once that, currently, it is 
used to treat infections caused by Candida species, Cryptococcus species and Aspergillus species (5). 
 
 
Figure 1.12 - Chemical structure of flucytosine. Adapted from (64). 
 
Furthermore, the prevalence of primary resistance to this antifungal is low because it is not 
used as first option in clinic. Though, resistance mechanisms to flucytosine are associated above all 
to mutations in cytosine permease, cytosine deaminase or in UMP pyrophosphorylase (61). These 
mutations interfere in intracellular enzymatic steps of action mechanism of 5-flucytosine, causing 
resistance. The increase in the production of pyrimidines can also contribute to resistance to this 
agent (5). 
 
1.4.2.4. Echinocandins 
Echinocandins (Figure 1.13) is another class of antifungal agents. These are responsible for 
the inhibition of the enzyme ß-1,3-D-glucan synthase, that in turn leads to the inhibition of the 
biosynthesis of ß-1,3-D-glucan, an important constituent of the fungal cell wall (63). Consequently, the 
disruption of cell wall structure occurs, which results in the osmotic instability and cell death. The 
toxicity of these antifungal is low because their target is not present in the mammalian cells (65). 
  There are three types of echinocandins: caspofungin, micafungin and anidulafungin. They 
have been used to treat infections caused by Candida species, including C. albicans, C. glabrata and 
C. tropicalis (5). 
 Nevertheless, C. albicans and NCAC species have revealed some resistance to 
echinocandins. This resistance is induced by mutations in the two important regions of FKS1 (HS1 
and HS2), the gene responsible for the encoding of the major and presumed catalytic subunit of ß-
1,3-D-glucan synthase complex. It is important to refer that, into C. glabrata, the resistance can also 
be due to the point alterations in the FKS2 gene (63). 
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Figure 1.13 - General structure for echinocandins (65). 
 
1.4.3. Resistance mechanisms of fungal biofilms 
The first study about the resistance of Candida biofilms to antifungal agents was published in 
1995 (72). Since then, several authors have presented studies about fungal biofilms resistance 
mechanisms, but some of these are not yet fully understood (5). 
Biofilms exhibit greater antifungal resistance in comparison with planktonic cells (circa 10-
1000 times more) (16). While in planktonic cells, the resistance is due mainly to genetic mutations, 
as already mentioned above, in biofilms, the resistance results from the physical structure and 
density of population, for example, regardless of the existence of changes in the genes (71). 
Thus, antifungal resistance in biofilms is a complex and multifactorial mechanism. Factors as 
physiological state, cell density, overexpression of drug targets, efflux pumps, ECM, persister cells and 
stress, can lead to resistance into biofilms (Figure 1.14) (71). 
 
 
Figure 1.14 - Representation of the resistance mechanisms of fungal biofilms (71). 
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1.4.3.1. Physiological state 
Firstly, it is necessary to mention the growth rate. Studies have reported that the growth rate 
of C. albicans in biofilms does not influence its resistance to amphotericin B. On the other hand, the 
growth of C. albicans biofilms in glucose and iron limited conditions and in anaerobic conditions 
causes a high resistance to amphotericin B and to azole agents (71). 
In addition, the metabolic activity should also be considered. Chandra et al. demonstrated 
that metabolic activity of C. albicans biofilms increases during biofilm formation. This fact suggests 
that dormant or dead cells do not cause the resistance in these biofilms. Thus, these investigations 
propose that the physiological state plays a minimal role in the antifungal resistance of C. albicans 
biofilms (73). 
 
1.4.3.2. Cell density 
This is an important resistance factor, mainly to azoles. In mature biofilms, characterized 
usually by a high cell density, there is spatial heterogeneity between microcolonies and water 
channels, which induces the resistance. It is also believed that the cell density into biofilms causes 
recalcitrance to drugs (71). 
Another situation associated to dense biofilms is the cooperation that exists between 
individual cells. This phenomenon occurs by quorum sensing processes, conferring biofilm cells the 
ability to coordinate its behaviour through the secretion of signalling molecules. Anyway, resistance 
mechanisms related to this factor still need more studies for a better understanding (71). 
 
1.4.3.3. Overexpression of drug targets 
Ergosterol has a great importance in biofilm resistance, mostly to azoles, which avoid their 
synthesis. The increase of reported ergosterol genes justifies this reality (71). Mukherjee et al. (73) 
demonstrated that ergosterol levels decreased 41% in intermediate biofilms (12 h) and 50% in 
mature biofilms (24 h), compared with the early phase of C. albicans biofilm. In fact, during biofilm 
formation of C. albicans, the level and the composition of sterol varies, contributing to antifungal 
resistance. These variations can be explained by genes overexpression of ergosterol biosynthesis (73). 
Another study made in young and mature C. albicans biofilms exposed to amphotericin B 
and fluconazole, has shown interesting results. In both biofilms exposed to amphotericin B, it was 
verified an overexpression of CaSKN1 and an upregulation of CaKR1 (genes from the ß-1,6-glucan 
pathways), while in the biofilms exposed to fluconazole, mainly in the mature biofilms, it was detected 
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an upregulation of genes responsible for enzymes encoding that intervene in ergosterol biosynthesis 
(CaERG1, CaERG3, CaERG11 and CaERG25) (71). 
Further researches were developed in other Candida biofilms (e.g., C. dubliniensis and C. 
parapsilosis) in contact with antifungals, but the conclusion was the same: the changes in the cell 
membrane and cell wall, caused by overexpression or upregulation of genes involved in the synthesis 
of ergosterol and glucans, respectively, interfere in the antifungal resistance of fungal biofilms (71). 
 
1.4.3.4. Drug efflux pumps 
In a study (73) about antifungal resistance of C. albicans biofilms, it was evaluated the efflux 
pumps influence in the early phase of biofilms formation. In this same investigation, resistance was 
also analysed in a triple deletion background. The results obtained allowed to conclude that the 
susceptibilities to azole of biofilms, produced by efflux pump mutants, varied in function of the 
number of pumps deleted and of the biofilm formation phase. Early phase of biofilms formed by the 
triple knock-out mutant strain revealed to be susceptible to azoles, while the susceptibilities to 
fluconazole decreased in mature biofilms formed by the same strain. 
Another study, where efflux pumps marked with a fluorescent substrate (Rhodamine123) 
were used, the highest levels of Rhodamine123 were detected in the early phase of biofilm rather 
than in intermediate and mature phases (73). 
Therefore, these studies have demonstrated that the efflux pumps contribute to antifungal 
resistance of biofilms in the early phase of their formation. In the next stages, this is not verified. 
Moreover, during biofilm development, there are differentially expressed efflux pumps (73). 
 
1.4.3.5. Extracellular matrix 
ECM plays an important role in the antifungal resistance of biofilms, because it is a structure 
that protects pathogenic cells from immune response of the host and hampers the antifungal agents 
diffusion (71, 73). 
 In biofilms of C. albicans and C. tropicalis, ECM has a complex composition. ß-1,3-glucans 
are mainly the carbohydrate components in ECM of C. albicans biofilms. Studies have shown that 
these constituents increase throughout biofilm development, over-intensifying the resistance of ECM. 
Moreover, investigations, conducted by Andes group (71), allowed to conclude that ß-1,3-glucan acts 
as a “drug sponge” because it has also the function of sequester over several antifungal agents such 
as azoles, echinocandins, pyrimidines and polyenes. 
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 Another aspect that it is necessary to mention is associated with the ECM regulation. There 
are many components that play an important role in the matrix production such as the 
glucoamylases (CaGCA1 and CaGCA2) and the alcohol dehydrogenases (CaADH5, CaCSH1 and 
CaLFD6), in which these latter form quorum-sensing aryl and acyl alcohols. Thus, it is suggested that 
the ECM formation of C. albicans biofilms is highly regulated by the combined action of previous 
substances, which constitutes another resistance mechanism (71). 
 
1.4.3.6. Persister cells 
Persister cells are “dormant variants of regular cells that form stochastically in microbial 
populations and are highly tolerant to antibiotics” (74). They are mainly responsible for the antifungal 
resistance in chronic infections (71). 
In C. albicans biofilms, it was reported the existence of persister cells to amphotericin B. In 
the same study, the death cells of biofilm were reinoculated and a new biofilm was formed with a new 
subpopulation of persister cells, corresponding to phenotypic variants of a wild type. Besides, the 
existence of persister cells against amphotericin B has been described, in C. krusei and C. 
parapsilosis biofilms (71, 75). 
Anyhow, the discovery of this resistance mechanism in fungal biofilms is relatively recent 
(2006). So, further research should be realized (71). 
 
1.4.3.7. Stress 
Stress is another important factor in resistance mechanism to antifungal agents. Normally, 
changes in temperature, ionic stress, osmotic changes or oxidative stress cause a physiological 
stresses in pathogenic microorganisms, such as Candida species. When these stresses reach the host 
receptors, conserved signalling pathways (e.g., mitogen-activated protein kinase (MAPK) signal 
transduction network) are automatically activated. In the example given above, the MAPK Mck1p 
interferes in biofilm formation and, in its no mutated form it is susceptible to azole agents. This fact 
leads to believe that Mck1p cause biofilm resistance as a consequence of a stress pathway (71). 
Calcineurin is another example of the phenomenon described above. Some studies show that 
calcineurin is involved in resistance to azoles agents in the development of biofilms (71).  
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2.1. Introduction 
The emergence of new Candida species (NCAC species), associated to fungal infections in 
humans, has significantly increased in the last two decades (5). The main causes of this 
phenomenon are the increase of immunosuppressed patients, the intensive use of antifungal agents, 
the improvements in diagnostic methods (such as the use of chromogenic agar media and molecular 
tools to differentiate species) and the development of new identification techniques (4, 5, 76). 
The genus Candida integrates yeasts that do not have a known sexual stage nor any other 
remarkable phenotypic characteristics (77). In this taxonomic group, where there is a stronger 
diversity of microorganisms biologically different from each other (including ascomycetous and 
basidiomycetous yeasts), it is possible to find about 200 species (1). Generally, the members of this 
genus are characterized in terms of colonial morphology, carbohydrate utilization and fermentation 
(78). Thus, these species have been described as being able to form oval colonies, in SDA medium, 
and spherical or oval cells, in standard conditions. The filamentous structures formation (hyphae or 
pseudohyphae) has also been verified for some Candida species. Regarding the fermentation, several 
sugars (depending on the species) have been involved in this process as well (5). 
Of all pathogenic Candida species found in humans, C. albicans is the most prevalent and 
the most pathogenic (25, 26). This polymorphic microorganism, due to its ability to produce hyphae 
and/or pseudohyphae, is the main cause of candidiasis (5, 14). Concerning NCAC species, C. 
glabrata, C. parapsilosis and C. tropicalis are the most frequent causes of candidiasis after C. 
albicans. While C. glabrata does not form any filamentous structure, the opposite has been detected 
for the other two species (5). 
In addition to these, other Candida species have been discovered. Recently, and from an 
epidemiological study of candidiasis performed in Portugal, a new pathogenic Candida species was 
found – Candida bracarensis. Initially, this anamorphic yeast was phenotypically confused as C. 
glabrata, but later studies showed significant differences between both species (1, 4). 
Unfortunately, there are still few studies about the characteristics of C. bracarensis 
comparatively to C. albicans and C. glabrata, for example. Therefore, the focus of this chapter was to 
characterize three strains of C. bracarensis, concerning its colonies in CHROMagarTM Candida, its cells 
morphology in three distinct culture media and its growth kinetics. It is also important to refer that the 
information presented in this chapter was essential for understanding some concepts analysed in the 
following chapters.  
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2.2. Materials and methods 
2.2.1. Organisms 
A total of three isolates of Candida bracarensis were used in this study. The first strain (NCYC 
3133) was isolated at the United Kingdom from a central venous catheter; and the second strain 
(153 MT) was obtained from a vaginal sample of a patient with candidoses, at the Hospital of São 
Marcos (Braga, Portugal). The third strain (CNM-CL-7030) belongs to the Spanish National Centre for 
Microbiology Yeast Collection and it was isolated from a catheter exudate of a patient in a critical 
condition. Strains NCYC 3133 and 153 MT were identified as being Candida bracarensis by the 
Department of Biology, University of Minho (Braga, Portugal) (4), while CNM-CL-7030 identification 
was confirmed by the Spanish Reference Mycology Laboratory (56). The identification of these 
isolates was performed by sequencing the D1/D2 domain of the 26S rDNA and ITS1/ITS2 regions. 
Additionally, two reference strains of Candida albicans (ATCC 90028) – the Candida species more 
studied at all levels – and Candida glabrata (ATCC 2001) – the species that presents more similarities 
with C. bracarensis –, from the American Type Culture Collection (ATCC), were also examined (4, 5, 
52). 
 
2.2.2. CHROMagarTM Candida identification 
Strains were cultured on CHROMagarTM Candida (CHROMagar, BioMerieux, Paris, France) 
and incubated for 48 h at 37°C. The species were differentiated, after 48 h, by the respective 
colonies’ color. This procedure was essential to confirm the strains purity. 
 
2.2.3. Epifluorescent microscopy 
2.2.3.1. Media and growth conditions 
All microorganisms were subcultured on yeast peptone dextrose (YPD) agar medium, which 
was composed by 1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) glucose and 2% (w/v) agar. 
After an incubation period of 24 h at 37°C in YPD agar, the yeast cells were grown in YPD broth (1% 
(w/v) yeast extract, 2% (w/v) peptone and 2% (w/v) glucose) for 18 h at 37°C with constant 
agitation (120 rpm). Afterwards, the suspensions were centrifuged at 3000 g for 10 min at 4°C to 
recover the cells. The recovered cells were washed twice with phosphate-buffered saline (PBS; pH 7.5, 
0.1 M) and counted using a Neubauer counting chamber. The yeast cells were then resuspended to a 
final concentration of 1.0×105 cells/ml in three distinct culture media (namely YPD broth, RPMI 1640 
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(Sigma, Saint Louis, Missouri, USA) and in a hyphae inductor medium) and incubated for 24 h at 
37°C, in an orbital shaker (120 rpm). The hyphae inductor medium consisted in equal volumes of 
RPMI 1640 (Sigma) and fetal bovine serum (FBS) (GIBCO, New York, USA). 
 
2.2.3.2. Calcofluor white staining 
After 24 h of incubation in each medium (YPD, RPMI 1640 and hyphae inductor medium), 
100 µl of yeast cell suspension were centrifuged at 5000 rpm for 5 min, and the pellets obtained 
resuspended and incubated with 50 µl of calcofluor white (Sigma), for 5 min at room temperature. 
Finally, the cells were washed twice with PBS and placed on microscope slides. All samples were 
visualized using an Olympus BX51 epifluorescence microscope with a DP71 digital camera coupled 
(Olympus Portugal SA, Porto, Portugal), which allowed the visualization of the morphology and 
determination of the average size (µm) of the yeast cells. This procedure was also repeated for a 
sample removed from cell suspension of each strain, in YPD medium, after 6 h of growth. 
 
2.2.4. Growth kinetics 
One colony of each strain was suspended in 30 ml of YPD medium at 37°C and 120 rpm. 
After 18 h, cells were centrifuged at 3000 g for 10 min at 4°C and washed twice with PBS (pH 7.5, 
0.1 M). Then, the yeasts were enumerated using a Neubauer counting chamber and adjusted to a 
concentration of 1.0×105 cells/ml in YPD and RPMI 1640 (Sigma) media. Afterwards, cell 
suspensions were incubated at 37ºC at 120 rpm and the species growth determined by optical 
density measurement at 620 nm, with MultiskanFC microplate reader (Thermo Scientific, Waltham, 
USA), and during different time points up to 24 h. Later, a relationship between absorbance values 
and the number of cells was established, allowing the growth kinetics curves construction. Specific 
growth rate (µ) in the exponential stage was also determined from the slope of the straight line, 
according to the equation ln Xt=ln Xt0+µt (where Xt0 is the cell concentration in the beginning of the 
exponential growth and Xt is the cell concentration at time t) (79). 
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2.3. Results 
2.3.1. Candida bracarensis identification through CHROMagarTM 
Candida 
CHROMagarTM Candida was used to confirm the purity and to determine Candida colonies 
morphological characteristics (Figure 2.1). In this medium, all species presented colonies with an oval 
shape, a smooth texture, but with different colors. Green colonies were identified for C. albicans, while 
pink colonies were observed for C. glabrata. Concerning the C. bracarensis, these strains formed 
white (or cream-colored) colonies. 
 
 
Figure 2.1 - Identification of C. albicans ATCC 90028, C. glabrata ATCC 2001, C. bracarensis NCYC 3133, C. bracarensis CNM-CL-7030 and C. 
bracarensis 153 MT species by CHROMagar. 
 
2.3.2. Candida bracarensis morphology analysed by epifluorescent 
microscopy 
Epifluorescent microscopy was used to determine morphological characteristics and to verify 
the presence of hyphae formation by Candida species. Some studies (80, 81) have reported that the 
yeast cells’ characteristics vary with different culture media. For that reason, in the present study, 
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strains were analysed after 6 and 24 h of growth in three distinct media: a rich (YPD), a poor (RPMI 
1640) and a hyphae inductor medium. 
 
2.3.2.1. Six hours of growth in YPD medium 
In Figure 2.2, it is possible to observe the morphology of C. bracarensis cells after growing 6 
h in the rich medium (YPD). C. albicans and C. glabrata were used as controls. 
 
  
  
  
  
 
 
Figure 2.2 - Epifluorescent microscopy images of Candida species stained with calcofluor white after 6 h of growth in YPD medium: (a) C. albicans ATCC 
90028, (b) C. glabrata ATCC 2001, (c) C. bracarensis NCYC 3133, (d) C. bracarensis CNM-CL-7030 and (e) C. bracarensis 153 MT. 
 
(a) (b) 
(c) (d) 
(e) 
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 Figure 2.2 shows that all Candida strains produced cells with an elliptic or oval shape, but 
with different dimensions: the three strains of C. bracarensis (NCYC 3133 – 1.0 × 1.3 µm, CNM-CN-
CL 7030 – 1.0 × 1.1 µm, 153 MT – 1.2 µm) formed cells bigger than C. glabrata ATCC 2001 (1.0 
µm) and smaller than C. albicans ATCC 90028 (1.4 × 1.7 µm). For each species, it was also 
detected that cells appeared grouped and with the chitin clearly marked by calcofluor white, mainly in 
C. bracarensis NCYC 3133. Furthermore, it was not observed any hyphae and pseudohyphae 
formation in the studied strains, after 6 h of growth in this medium. 
 
2.3.2.2. Twenty four hours of growth in YPD, RPMI and in an hyphae inductor 
medium  
In Table 2.1, it is possible to observe the images of Candida species after 24 h in YPD 
medium, to compare with the one images obtained in point 2.3.2.1.; in RPMI, a medium used to 
mimic body fluids; and in hyphae inductor medium, used to allow the possible observation of hyphae 
formation by these yeasts. Moreover, complementary and summary information can be found in 
Table 2.2. 
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Table 2.1 - Epifluorescent microscopy images of Candida species stained with calcofluor white after 24 h of growth in different culture media 
Species YPD medium RPMI medium 
Hyphae inductor medium 
[50% RPMI + 50%FBS (v/v)] 
Candida 
albicans 
ATCC 90028 
   
Candida 
glabrata 
ATCC 2001 
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Candida 
bracarensis 
NCYC 3133 
   
Candida 
bracarensis 
CNM-CL-
7030 
   
Candida 
bracarensis 
153 MT 
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 The images presented in Table 2.1 demonstrate that, at the end of a 24 hour growth in each 
culture media, C. bracarensis strains did not produce either germ tube or hyphae/pseudohyphae like 
the C. glabrata, but unlike C. albicans. Furthermore, C. albicans formed filamentous structures, but 
only in RPMI and hyphae inductor medium. In addition, it was observed that C. glabrata and C. 
bracarensis 153 MT formed oval cells, while the other strains presented cells with an elliptic shape. 
Regardless of the culture medium, it was also possible to verify that the Candida cells may 
appear singly or grouped, being this latter situation more common in the images of Table 2.1. 
As referred, all the information is summarized in Table 2.2. 
 
Table 2.2 - Morphological characteristics of C. albicans ATCC 90028, C. glabrata ATCC 2001, C. bracarensis NCYC 3133, C. bracarensis CNM-CL-7030 
and C. bracarensis 153 MT species, after 24 h of growth in different media culture 
Species 
Germ tube 
production 
Hyphae/ 
pseudohyphae 
Cells 
shape 
Cells size (µm) 
YPD medium RPMI medium 
Hyphae inductor 
medium 
C. albicans 
ATCC 90028 
+ +/+ Elliptic 1.3 × 1.7 1.9 × 2.2 2.1 × 3.1 
C. glabrata 
ATCC 2001 
- -/- Oval 1.0 1.0 1.0 
C. bracarensis 
NCYC 3133 
- -/- Elliptic 1.1 × 1.9 0.9 × 1.2 1.0 × 1.9 
C. bracarensis 
CNM-CL-7030 
- -/- Elliptic 1.0 × 1.7 1.2 × 1.7 0.8 × 1.5 
C. bracarensis 
153 MT 
- -/- Oval 1.6 1.6 1.5 
Yes (+); No (-). 
 
According to Table 2.2, cell size remained relatively constant among the three culture media 
and for each studied species, with exception of C. albicans, which presented smaller cells in YPD 
than in the other two media. However, similar to the results of 6 h of growth (Figure 2.1), it was 
verified for all media that C. bracarensis presented bigger cells than C. glabrata, but smaller than C. 
albicans. It is also important to notice that the 153 MT was the strain that showed the bigger cells 
between the C. bracarensis species. 
 
2.3.3. Growth kinetics of Candida bracarensis strains 
The growth kinetics curves of C. bracarensis strains in YPD and RPMI medium are 
represented in Figure 2.3. In the same figure are also represented the growth curves of C. albicans 
ATCC 90028 and C. glabrata 2001, only for comparison. 
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(a) (b) 
 
Figure 2.3 - Growth curve (Log10 (cells/ml) vs time(h)) of C. albicans ATCC 90028, C. glabrata ATCC 2001, C. bracarensis NCYC 3133, C. bracarensis 
CNM-CL-7030 and C. bracarensis 153 MT, in (a) YPD and (b) RPMI medium. 
 
Through the analysis of Figure 2.3, it is possible to identify the different growth phases of the 
studied species. So, the lag phase occurred in the first 2 h in YPD, and in the first 4 h in RPMI. This 
phase is characterized by an adaption of strains to the new environment which involves changes 
either in the physiology or the metabolism of cells (79, 82). After 2 h and 4 h, the exponential phase 
started in YPD and in RPMI medium, respectively. This stage took place until the 8th hour of growth in 
both media, because there was an increase in the cell concentration accompanied by a high specific 
growth rate (Table 2.3). Finally, the stationary phase occurred between the 8th and 24th hour of growth 
in both culture media, where the cell concentration remained constant (79, 82). 
Figure 2.3 also shows that during the growth time, all Candida species had similar 
behaviours between them and in the two media. Nevertheless, in YPD medium, the strains reached a 
higher cell concentration than in RPMI medium, at the end of 24 h of growth. 
It is also important to refer that in YPD medium (Figure 2.3 (a)), the growth curves of strains 
NCYC 3133 and 153 MT were almost identical. For the time interval 0-10 h, these two species 
exhibited a nearest growth of C. albicans than of C. glabrata, contrary to what was observed for C. 
bracarensis CNM-CL-7030. In relation to RPMI medium (Figure 2.3 (b)), it was verified that the 
growth curves of C. albicans and C. bracarensis CNM-CL-7030 were coincident between the 4th and 
24th hour. C. bracarensis NCYC 3133 had also a nearest behaviour of C. albicans than of C. glabrata, 
while C. bracarensis 153 MT presented an intermediate behaviour in the time interval 4-10 h, 
comparatively to the other Candida species. 
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Regarding the specific growth rates determined (Table 2.3), it was found that the rates were 
higher in RPMI than in YPD. In this last medium, C. albicans presented the largest rate, while C. 
bracarensis NCYC 3133 had the smallest one in comparison to the other Candida species. In RPMI 
medium, the smallest rates were detected in two strains of C. bracarensis – NCYC 3133 and 153 MT. 
In contrast, the largest rate was obtained by C. glabrata in that medium. 
  
Table 2.3 - Specific growth rate (µ) of C. albicans ATCC 90028, C. glabrata ATCC 2001, C. bracarensis NCYC 3133, C. bracarensis CNM-CL-7030 and C. 
bracarensis 153 MT species 
Species 
µ (h-1) 
YPD medium RPMI medium 
C. albicans ATCC 90028 0.7300 0.8014 
C. glabrata ATCC 2001 0.6863 0.8520 
C. bracarensis NCYC 3133 0.6590 0.7555 
C. bracarensis CNM-CL-7030 0.7154 0.8169 
C. bracarensis 153 MT 0.7086 0.7231 
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2.4. Discussion 
In general, the results obtained in this chapter showed significant differences between the 
three C. bracarensis strains and C. albicans ATCC 90028. Differences between C. bracarensis and C. 
glabrata ATCC 2001 were also detected, but in smaller proportions. This last observation possessed 
higher significance once C. bracarensis was initially identified as C. glabrata, due to similar 
physiological characteristics between the two species (1, 4). Despite some similarities in terms of 
phenotype, the differences found in this work are sufficient to emphasize the incorrect identification of 
C. bracarensis as C. glabrata, a fact already presented by Warren et al. (53). 
 On CHROMagarTM Candida (Figure 2.1), all C. bracarensis strains formed white colonies, 
unlike C. albicans or C. glabrata, which produced green and pink colonies, respectively. All these 
results are in agreement with those described in the literature (13, 22, 60). There are, inclusive, some 
authors (52, 53) that identified white colonies for other strains/isolates of C. bracarensis, in addition 
to those analysed in this work. Through these data, it is possible to refer that CHROMagarTM Candida 
is an important screening tool for a presumptive identification of a mixture of C. albicans, C. glabrata 
and C. bracarensis (52). Additionally, all studied strains presented colonies with an oval shape and a 
smooth texture. The same had already been demonstrated for C. albicans and C. glabrata, grown on 
chromogenic agar medium, by Odds et al. (22). Concerning C. bracarensis, these morphological 
characteristics have also been described for strains NCYC 3133 and 153 MT, but in another agar 
media (54, 55). 
 In respect to the morphology analysed by epifluorescent microscopy (Figure 2.2 and Table 
2.2), it was demonstrated that, in YPD medium, all C. bracarensis strains presented bigger cells after 
24 h of growth than only after 6 h. This difference can be justified by the results of growth kinetics of 
these species in the same medium (Figure 2.3 (a)). In fact, 6 h later, the cells were still in the 
exponential phase, i.e., they were still under development. On the other hand, at 24 h (stationary 
phase), the morphological development of the cells has already been concluded, and metabolic 
functions were still active (79). Nevertheless, the same comparison between the two times (6 and 24 
h) was not detected for C. albicans and C. glabrata. 
Concerning the yeasts’ size, it was also verified that all C. bracarensis strains formed bigger 
and smaller cells than C. glabrata and C. albicans, respectively. This observation was common at 6 
and 24 h of growth and in the three culture media tested (Figure 2.2 and Table 2.2). However, all C. 
bracarensis strains presented dimensions lower than those indicated by Correia et al. (4) for strain 
153 MT grown in YM broth (oval shape: 3.0-3.5 µm; ellipsoidal shape: 3.0-4.0 × 4.0-4.5 µm). In the 
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case of C. albicans, its cell sizes were also lower than those reported by Calderone (4-6 × 6-10 µm) 
(13). In opposition, C. glabrata was the only strain, whose cell size was coincident (1-4 µm) (13). The 
differences found between this study and the literature can be associated to the use of distinct 
methods for the determination of cell size. The composition of different culture media can explain this 
discrepancy as well (80, 81), although, in the present work (Table 2.2), few significant differences 
had been found at level of the yeasts’ size grown in YPD, RPMI and hyphae inductor medium (with 
exception of C. albicans). 
Furthermore, in all cases analysed (Figure 2.2 and Table 2.1), all cells of C. bracarensis 
appeared mostly in pairs, like C. albicans and C. glabrata. It is also important to refer that the same 
had already been detected for C. bracarensis 153 MT grown in YM broth (4). The presence of chitin, 
marked by calcofluor white, was also verified for all the species under study. In fact, the chitin has 
been indicated as an important carbohydrate of the cell wall of Candida species, presenting larger 
amounts in cell wall of C. albicans than of C. glabrata (21). Nonetheless, the images obtained were 
inconclusive about the strains that showed more or less chitin in their cell walls. 
Among C. bracarensis species, 153 MT was the strain that presented the bigger cell size and 
the only one that formed oval cells in the three culture media (Table 2.2). The oval shape was verified 
only for C. bracarensis 153 MT and C. glabrata which enables affirming that there is a higher degree 
of morphologic similarity between these two microorganisms than between C. glabrata and the strains 
NCYC 3133 and CNM-CL-7030. It is necessary to mention that these last two strains of C. 
bracarensis presented cells with an elliptic shape, such as C. albicans. 
Regarding the filamentous structures production (Figure 2.2 and Table 2.1), and regardless 
the growth time or medium used, it was observed that no C. bracarensis strain formed hyphae 
and/or pseudohyphae, in similarity to C. glabrata. These results reinforce the anamorphic character 
of these two species, a fact already demonstrated by other investigators (1, 4, 13). On the other 
hand, the growth of hyphae and pseudohyphae was verified for C. albicans, what is also in 
accordance to the described in the literature (14, 15). However, the presence of these filamentous 
structures was detected only in RPMI and hyphae inductor medium, and not in YPD medium. The 
cause of this situation is associated to the composition of the culture media. Indeed, in RPMI 1640 
and hyphae inductor medium, there are compounds (such as L-glutamine) that stimulate the germ 
tube production and, consequently, the hyphae growth (83, 84). The serum (FBS) contained in the 
hyphae inductor medium is also considered an important factor for induction of these filamentous 
structures (14, 15). Nevertheless, in YPD medium, there are none of these compounds (85), what 
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may have made the difference. In this sense, some authors (86-89) have used the YPD medium for 
the growth of C. albicans cells in the yeast form, and YPD containing serum (or only RPMI 1640) for 
the hyphal induction in the same Candida species. 
Growth kinetics of C. bracarensis, in YPD and RPMI media, was also analysed (Figure 2.3). 
The results showed that the curve shape presented by the three strains of C. bracarensis was similar 
to the one that has been reported for C. albicans (grown in shake culture) (90) or other fungi species 
(81). The different growth phases were also coincident between all studied species and in the two 
culture media, with the exception of the time interval 2-4 h. At this period, the cells cultivated in YPD 
medium had already entered in the exponential phase, while, in RPMI medium, the lag phase had not 
been concluded yet. Thus, and taking into account that the initial cell concentration was the same in 
both media, it is possible to refer that the adaptation of Candida species to physic-chemical 
environmental conditions was slower in RPMI than in YPD (79). In fact, it has been described that in 
poor media, such as RPMI, the fungi grow slower (81). The same justification can be used to explain 
the low cell concentrations obtained in RPMI (at the end of 24 h of growth), comparatively to what 
was verified in YPD medium. 
In contrast, it was found that the specific growth rates of all Candida species were higher in 
RPMI than in YPD (Table 2.3). Although it is a poor medium (81), the present study showed that 
RPMI was the most effective in the division of the cell population, allowing the formation of a higher 
number of generations per time. The origin of this situation may eventually be associated with 
intrinsic physiological characteristics of strains and/or extrinsic environmental factors (for example, 
pH, oxygen, nature and concentration of nutrients). In the particular case of YPD medium, the high 
concentration of glucose (compared to RPMI) may have contributed to increase the production and 
accumulation of metabolic products, therefore constituting an obstacle to the growth of strains (79). 
Moreover, and among studied species, it was detected that C. bracarensis CNM-CL-7030 was 
the only strain that presented high growth rates in both media, while the opposite was verified for C. 
bracarensis NCYC 3133. This observation proved that the cell division was faster in strain CNM-CL-
7030 and slower in C. bracarensis NCYC 3133. However, it was not possible to establish a 
correlation between growth kinetics curves and the rates obtained, specifically in the exponential 
phase. For example, the curves of strains NCYC 3133 and 153 MT cultivated in YPD medium were 
almost identical (including in the exponential phase), but their growth rates were different from one 
another. 
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In conclusion, this work proved the existence of differences between C. bracarensis and the 
other Candida species, mainly in terms of colour of colonies formed on CHROMagar, cell size and 
specific growth rate. Alongside these differences, the formation of hyphae and/or pseudohyphae was 
not detected for C. bracarensis and C. glabrata, unlike C. albicans. The absence/presence of 
filamentous structures – a typical virulence factor of some Candida species – can have an important 
impact in the pathogenicity of these species (5), a fact that will be discussed in the next chapters 
(Chapters 3 and 4). Nevertheless, similarities were also found between studied species, essentially in 
the shape of colonies and cells, in the chitin contained in the cell wall and in the shape of the growth 
kinetics curve. 
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3.1. Introduction 
According to Odds et al. (91), virulence factors are defined as “factors that interact directly 
with mammalian host cells”. These components have a great impact on the pathogenicity of 
microorganisms such as Candida species (5). Therefore, the study on the virulence determinants of 
these species is important to the understanding of pathogenic mechanisms and to the emergence of 
new treatments (50). 
Among the several of Candida species that cause human infections, Candida albicans is the 
most frequent (mainly in the bloodstream infections) and the most pathogenic (25, 26). This last 
species is considered an endogenous commensal resident in the host tissue and commonly it is 
found in the yeast form with possible filamentous structures, which promote the invasion and, 
subsequently, the infection (91). Nevertheless, some authors (2, 53, 92) have reported that there are 
other important pathogenic members in the Candida group: C. tropicalis, C. dubliniensis, C. glabrata, 
C. parapsilosis, C. krusei and more recently C. bracarensis. Moreover, despite the significant increase 
of these NCAC species in the past two decades, there are still few studies on their virulence factors 
(5). Relatively to C. bracarensis, it was found no investigation focused in this thematic, since this 
species is recent (1). 
Virulence factors among the several Candida species are common, such as the ability to 
adhere to host tissues or medical devices, biofilm formation, hydrolytic enzymes production (e.g. 
proteases, phospholipases and haemolysins) and the ability to form filamentous structures as hyphae 
and pseudohyphae (1). Concerning the adhesion, this phenomenon is the first event in an infection 
caused by Candida species and is mostly influenced by cell wall proteins and cell surface 
physicochemical properties (10, 28). In the case of biofilms, a set of cells fixed to a surface and 
embedded in an ECM, its formation is dependent of strain, substrate properties and growth 
conditions (38, 39). Finally, the hydrolytic enzymes and the hyphae/pseudohyphae also are 
important virulence factors. While the enzymes are causative agents destruction, filamentous 
structures have a relevant role in the invasion of pathogen in the host tissue (5). 
In this sense, the main objective of work described in this chapter was to examine the 
presence of potential virulence factors in three C. bracarensis strains and to compare with the C. 
albicans and C. glabrata species. Specifically, it was evaluated their ability to adhere, forming biofilm 
(its matrix composition), and produce hydrolytic enzymes.  
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3.2. Materials and methods 
3.2.1. Organisms 
For this part of the work, the strains used were the same as described in section 2.2.1.; 
namely C. bracarensis NCYC 3133, C. bracarensis CNM-CL-7030, C. bracarensis 153 MT, C. albicans 
ATCC 90028 and C. glabrata ATCC 2001. 
 
3.2.2. Media and growth conditions 
For each experiment, strains were subcultured on YPD agar medium for 24 h at 37°C. Then, 
yeasts were cultured on YPD broth for 18 h at 37°C under agitation at 120 rpm. After incubation, 
cells were harvested by centrifugation (at 3000 g for 10 min at 4°C) and washed twice with PBS (pH 
7.5, 0.1 M). Afterwards, cells were enumerated using a Neubauer counting chamber and adjusted to 
a concentration of 1.0×107 cells/ml in YPD medium and in RPMI 1640 (Sigma) medium. 
 
3.2.3. Adhesion and biofilm formation 
For the adhesion and biofilm formation assays, 96-well polystyrene microtiter plates (Orange 
Scientific, Braine-l’ Alleud, Belgium) were used. To each well, 200 µl of the standardized cell 
suspensions (1.0×107 cells/ml in YPD and RPMI 1640) was added to the 96-well plates. The plates 
were incubated at 37°C in an orbital shaker at 120 rpm for 2 h, adhesion, or for 24 and 48 h for 
biofilm formation. To form and maintain 48 h biofilms, 100 µl of culture medium was removed and 
an equal volume of fresh medium was added, after 24 h. At the end of the respective times, the 
medium was removed and all wells were washed once with PBS (pH 7.5, 0.1 M), to remove the non 
adherent cells. Then, the results were assessed using colony forming units (CFUs) enumeration and 
by crystal violet (CV) method. Three independent assays were performed, each with triplicate 
samples. 
 
3.2.3.1. Colony forming units enumeration 
To determine the number of CFUs, 200 µl of PBS was added to each well and then the 
adherent cells were detached from the surface by scrapping. This procedure was repeated twice and 
afterwards the suspension of each well was collected to the same container. The total cell 
suspensions (1200 µl) was vortexed for 5 min (to disrupt the biofilm matrix on the case of the biofilm 
formation assays) and, later, serial decimal dilutions (in PBS) were plated onto YPD agar and 
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incubated for 24 h at 37°C. The results were then expressed as the number of CFUs per unit area 
(Log10 CFUs/cm2). 
 
3.2.3.2. Crystal violet staining 
The CV method was used to determine the biomass of the biofilm (93). For that, after 
washing, 200 µl of methanol (100% v/v) was added to each well to fix the cells. Methanol was 
removed after 15 min of contact and the microtiter plates dried at room temperature. Afterwards, 200 
µl of crystal violet (1% v/v) was added to each well, which remained in contact with the cells for 5 
min. Then, CV was aspirated, the wells were washed twice with ultra-pure water and 200 µl of acetic 
acid (33% v/v) was added to dissolve the stain. Lastly, absorbance of CV solutions was read in a 
microtiter plate reader (Bio-Tek Synergy HT, Izasa, Lisbon, Portugal) at 570 nm and the values were 
standardized by unit area (Abs/cm2). 
 
3.2.4. Extracellular biofilm matrix composition 
3.2.4.1. Extraction method 
In order to analyse the composition of the extracellular biofilm matrix, 24-well polystyrene 
microtiter plates (Orange Scientific) were used, in which 1 ml of standardized yeast suspensions 
(1.0×107 cells/ml in YPD and RPMI 1640) were placed. Microtiter plates were incubated for 24 h and 
48 h at 37°C and 120 rpm. In the case of the 48 h biofilms, 500 µl of culture medium was removed 
and replaced by an equal volume of fresh medium, after 24 h. After biofilms formation, the culture 
medium was removed, wells were washed once with PBS (pH 7.5, 0.1 M) and cells were scraped 
from wells. The yeast cells were then resuspended in PBS, to a final volume of 5 ml. To determine the 
dry weight of each sample, 1 ml of the suspension was vortexed for 30 s, filtered through a 0.45 µm 
nitrocellulose filter and left to dry at 80°C for 24 h. The remaining 4 ml of suspensions, were 
sonicated (Ultrasonic Processor, Cole-Parmer, Illinois, USA), for 30 s at 30 W, and centrifuged at 
5000 rpm for 5 min at 4°C. The supernatant was filtered (through a 0.2 µm filter) and stored at -
20°C until protein and carbohydrate quantification. This assay was repeated three times for each 
strain and medium. 
 
3.2.4.2. Protein and carbohydrate quantification 
The content of protein present in the extracellular biofilm matrix was determined using the 
Bovine Serum Albumin (BSA) Kit (Bicinchoninic Acid, Sigma-Aldrich, St Louis, USA). A standard curve 
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(Figure A.1, in Appendix A) was performed using several solutions of BSA with known concentrations. 
Afterwards, the protein concentration was normalized by the biofilm dry weight. Thus, the quantity of 
proteins was present as mg of protein/g of biofilm dry weight. 
Carbohydrate present in the biofilm matrix were determined according the procedure 
described by Dubois et al. (94). For that, 0.5 ml of fenol (50 g/l) and 2.5 ml of sulfuric acid (95-97%) 
were added to 0.5 ml of each sample. This solution was vortexed for 30 s and incubated for 15 min 
at room temperature. The absorbance was read in a microtiter plate reader (Bio-Tek Synergy HT) at 
490 nm. A standard curve with glucose was also performed (Figure A.2, in Appendix A). Once again, 
the carbohydrate concentration was normalized by biofilm dry weight. Thus, the quantity of 
carbohydrate was present as mg of carbohydrate/g of biofilm dry weight. 
 
3.2.5. Proteolytic and phospholytic activity 
In order to analyse the protease activity, fresh cultured colonies were placed onto protease 
agar medium, containing 2% (w/v) agar, 1.17% (w/v) yeast carbon base, 0.01% (w/v) yeast extract 
and 0.2% (w/v) BSA with pH 5.0. Afterwards, the plates were incubated at 37°C for 4 days. After 
incubation, each plate of protease agar medium was placed in contact with 15 ml of dye solution 
(0.1% (w/v) amido black, 30% (v/v) methanol, 10% (v/v) acetic acid and 60% ultra-pure water) for 1 
h. Then the plates were washed twice with acetic acid (33% v/v) and dried at room temperature. 
Concerning the phospholipase activity, colonies were cultured onto phospholipase agar medium 
composed by 2% (w/v) agar, 1% (w/v) peptone, 2% (w/v) glucose, 1 M NaCl, 5 mM CaCl2 and 8% 
(w/v) egg yolk, followed by an incubation at 37°C for a period of 3 days. 
In the end, opaque halo degradation around the colonies grown was observed in both agar 
media, which allowed the determination of the presence or absence of enzymatic activity. Pz was 
assessed by the ratio between the colony diameter and the halo diameter plus the colony diameter, 
according to Price et al. (95). These assays were performed in triplicate and Candida tropicalis ATCC 
750 was used as positive control and C. glabrata ATCC 2001 as negative control, in particular in the 
proteolytic activity analysis (46, 49). In the case of phospholytic activity, Candida albicans ATCC 
90028 was the positive and C. glabrata ATCC 2001 used as negative control (96). 
 
3.2.6. Haemolytic activity 
In this experiment, fresh cultured colonies were placed inside of sugar-enriched sheep blood 
medium, with 2% (w/v) peptone, 1% (w/v) agar, 7% fresh sheep blood, 3% (w/v) glucose. The plates 
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were incubated at 37°C and 3 days later, the haemolytic activity was classified as absent (without 
halo), partial or total (transparent halo). This experiment was performed in triplicate and C. tropicalis 
ATCC 750 was used as a positive control (49). 
 
3.2.7. Statistical analysis of data 
Statistical analysis was performed using GraphPad Prism software for Windows. The two-way 
ANOVA with the Bonferroni post-hoc test was used to determine statistical differences between (i) the 
different culture media, (ii) the several strains studied and (iii) the different times of biofilm formation. 
All tests were performed with a 95% confidence level. 
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3.3. Results 
3.3.1. Adhesion ability of Candida bracarensis strains  
Adhesion ability of the three Candida bracarensis strains and the two references Candida 
species (C. albicans ATCC 90028 and C. glabrata ATCC 2001) were studied on polystyrene and two 
different culture media (YPD and RPMI). Figure 3.1 (a) presents the number of viable cells adhered 
enumerated by CFUs counts and Figure 3.1 (b) the total biomass values obtained by CV staining. 
 
  
(a) (b) 
 
Figure 3.1 - (a) Number of viable cells of Candida species per cm2 (mean ± standard deviation) and (b) absorbance values of CV solutions (Abs570nm/cm2) 
(mean ± standard deviation) obtained from 2 h of adhesion of Candida species in different culture media. Statistically different compared to YPD medium 
(*p<0.05; ***p<0.001). 
 
From Figure 3.1, it was possible to verify that all Candida strains were able to adhere to 
polystyrene in both media tested. Figure 3.1 (a) shows that the number of viable adhered cells in YPD 
medium was not statistically different from the number of cells obtained for RPMI (p>0.05), with 
exception for C. albicans (p<0.001). Moreover, no significant differences were observed among the 
three C. bracarensis strains under study (p>0.05). It is important to report that the three C. 
bracarensis strains adhered in both media in similar extension to the C. glabrata strain. 
Figure 3.1 (b) shows some statistical differences in the total biomass values between the two 
culture media in case of C. bracarensis strains, mainly concerning CMN-CL-7030 and 153 MT 
(p<0.001). In fact, C. bracarensis CNM-CL-7030 (with p<0.001 vs. C. albicans; with p<0.01 vs. C. 
glabrata and strain NCYC 3133) and C. bracarensis 153 MT (with p<0.001 vs. C. albicans, C. 
glabrata and strain NCYC 3133) produced higher biomass in RPMI medium, contrarily to C. albicans 
and C. glabrata species. In opposition, concerning the values obtained in YPD medium, C. 
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bracarensis strains presented lower values of biomass compared with C. glabrata and even C. 
albicans species, without significant statistically differences (p>0.05), though. 
 
3.3.2. Biofilms formation ability of Candida bracarensis strains  
Figure 3.2 presents the results relating to biofilm formation ability of the different strains and 
species under study, quantified using CFUs enumeration (Figure 3.2 (a, b)) and CV staining (Figure 
3.2 (c, d)). It was clearly evident that all Candida species studied were able to form biofilms, but with 
some differences concerning strains and conditions. 
 
  
(a) (b) 
  
(c) (d) 
  
Figure 3.2 - (a, b) Number of viable cells of Candida strains and (c, d) absorbance values of CV solutions per cm2 of biofilm formed in YPD and RPMI for 
24 and 48 h by different Candida species. Error bars represent standard deviation. Statistically different compared to 24 h biofilm (*p<0.05; **p<0.01; 
***p<0.001). 
 
 It is important to refer that in YPD medium all biofilms presented a similar number of viable 
cells at 24 h, with a significant increased for 48 h (p<0.05), with exception of C. albicans (p>0.05) 
(Figure 3.2 (a)). On the other hand, in RPMI medium (Figure 3.2 (b)), the opposite was detected, 
specifically in the strains NCYC 3133 and 153 MT (both with p<0.001), with biofilms with lower 
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number of viable cells at 48 h comparatively to 24 h counterparts. As for the 24 h biofilms in YPD 
and the 48 h biofilms in RPMI, no statistically significant differences were found between the strains, 
at least in terms of the number of viable cells (p>0.05). In the remaining conditions (48 h biofilms in 
YPD and 24 h biofilms in RPMI), C. bracarensis and C. glabrata presented a significant higher 
number of viable cells (p<0.05) than C. albicans. 
 Regarding the total biomass quantification values by CV staining (Figure 3.2 (c, d)), it was 
verified more relevant differences among strains and the conditions tested. In YPD medium (Figure 
3.2 (c)), all C. bracarensis strains presented similar values of total biomass at 24 h, however with 
statistically significant differences with C. glabrata biofilm, which presented the highest level of 
absorbance (Abs/cm2=0.93±0.02) (with p<0.001 vs. C. albicans and C. bracarensis). The same was 
observed in case of the 48 h biofilms. Moreover, no statistically differences were detected among the 
values of absorbance between 24 and 48 h biofilms, with exception of the biofilms of C. glabrata and 
C. bracarensis CNM-CL-7030, that were statistically higher at 24 h than at 48 h (p<0.001). 
Figure 3.2 (d) presents the CV results for biofilms formed in RPMI medium. In this figure, it 
was observed that 48 h biofilms of C. bracarensis strains NCYC 3133 and 153 MT had significantly 
lower level of biomass (p<0.001) in comparison with their 24 h biofilms. No statistically differences 
were found between the biofilms formed for 24 and 48 h (p>0.05) among the other strains. 
Furthermore, it is important to notice that C. bracarensis NCYC 3133 biofilms at 24 h and 48 h had 
significantly differences (p<0.05), presenting lower values of total biomass compared with the other 
Candida strains. While C. albicans and strain 153 MT presented the highest level of biomass at 24 h 
biofilms, only C. albicans biofilms at 48 h were statistically higher than the other strains (p<0.001 vs. 
C. glabrata and C. bracarensis). 
 
3.3.3. Extracellular biofilm matrix composition of Candida 
bracarensis strains 
Table 3.1 shows the total of protein and carbohydrates content extracted from biofilms 
matrices formed by different Candida species in YPD and RPMI for 24 and 48 h for each strain. 
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Table 3.1 - Protein and carbohydrates contents (mg/g of biofilm dry weight) extracted from biofilms matrices formed in YPD and RPMI for 24 and 48 h by different 
Candida strains. The values are means ± standard deviations 
Species 
Biofilm formation conditions Biofilm matrix composition (mg/g of biofilm dry weight) 
Culture medium Time (h) Proteins Carbohydrates 
C. albicans 
ATCC 90028 
YPD 
24 57.41 ± 2.55 100.77 ± 30.82 
48 46.85 ± 4.20 44.15 ± 8.08 
RPMI 
24 10.22 ± 1.96*** 38.15 ± 15.96** 
48 6.95 ± 5.46*** 31.13 ± 22.06 
C. glabrata 
ATCC 2001 
YPD 
24 53.60 ± 6.10 32.75 ± 9.06 
48 53.57 ± 10.85 44.34 ± 5.50 
RPMI 
24 7.57 ± 1.25*** 157.38 ± 40.48*** 
48 2.14 ± 0.42*** 62.40 ± 21.39 
C. bracarensis 
NCYC 3133 
YPD 
24 42.08 ± 1.90 111.63 ± 23.30 
48 47.47 ± 6.43 41.86 ± 14.48 
RPMI 
24 5.08 ± 0.29*** 58.07 ± 32.82* 
48 3.24 ± 1.79*** 39.53 ± 22.92 
C. bracarensis 
CNM-CL-7030 
YPD 
24 76.57 ± 5.17 45.87 ± 17.73 
48 59.22 ± 8.32 55.29 ± 25.85 
RPMI 
24 12.98 ± 6.46*** 34.47 ± 10.34 
48 12.89 ± 1.92*** 38.58 ± 13.25 
C. bracarensis 
153 MT 
YPD 
24 57.06 ± 11.38 83.06 ± 27.19 
48 60.60 ± 7.46 28.76 ± 20.96 
RPMI 
24 1.70 ± 1.10*** 45.17 ± 21.98 
48 8.03 ± 4.80*** 36.83 ± 6.53 
Statistically different compared to biofilm matrix formed in YPD for 24 and 48 h, respectively (*p<0.05; **p<0.01; ***p<0.001). 
  
Concerning protein quantification, the results (Table 3.1) showed differences between the two 
culture media: the protein amount extracted from matrices of biofilms formed in YPD was statistically 
higher (p<0.001) than in RPMI medium. On the other hand, no statistically significant differences 
(p>0.05) were detected between the protein levels extracted from 24 and 48 h biofilms formed in the 
same medium, except for C. bracarensis CNM-CL-7030 biofilm formed in YPD (p<0.01). In addition, 
it was also evident that C. bracarensis CNM-CL-7030 presented a statistically higher protein content 
in 24 h biofilm matrix in YPD compared with the other biofilms formed in the same conditions 
(p<0.001 vs. C. albicans, C. glabrata and strain NCYC 3133; p<0.01 vs. strain CNM-CL-7030). 
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In relation to the carbohydrate quantification, the differences between the two culture media 
were significantly lower than those observed in the case of proteins. Only C. albicans (p<0.01), C. 
glabrata (p<0.001) and C. bracarensis NCYC 3133 (p<0.05) presented significantly higher levels of 
carbohydrate at 24 h biofilms in RPMI compared to its respective 24 h biofilms in YPD medium. 
Furthermore, the carbohydrate content extracted from 24 h biofilms was significantly higher than in 
48 h biofilms formed in the same medium, but only for specific strains: C. albicans (p<0.05), C. 
bracarensis NCYC 3133 (p<0.01) and C. bracarensis 153 MT (p<0.05), in YPD medium; and C. 
glabrata (p<0.001), in RPMI medium. It was also verified that biofilm matrix formed in RPMI for 24 h 
by C. glabrata had significantly higher quantities of carbohydrate than the other biofilm matrices 
formed in the same conditions (p<0.001 vs. C. albicans and C. bracarensis). In the remaining 
conditions of biofilm formation, there were no statistically differences between the strains. 
 
3.3.4. Proteolytic, phospholytic and haemolytic activity by Candida 
bracarensis strains 
In Figure 3.3, it is possible to observe the results of the enzymatic activity for Candida 
species. The results are present as presence or absence of an opaque halo of degradation around the 
colonies when grown on specific agar medium. Moreover, the Pz values were also determined (in the 
case of proteolytic and phospholytic activity) according to Price et al. (95). Thus, Pz=1.00 means that 
there is no enzymatic activity, while a value of Pz<1.00 indicates the opposite. In addition, C. 
tropicalis ATCC 750 was used as positive control in the proteases and haemolysins production, while 
C. albicans ATCC 90028 was the positive in the phospholytic activity (46, 49, 96). 
 
   
     (a) (b) (c) 
Figure 3.3 - Images showing the effect of secreted (a) proteases, (b) phospholipases and (c) haemolysins by Candida species (C. tropicalis ATCC 750, C. 
albicans ATCC 90028, C. glabrata ATCC 2001, C. bracarensis NCYC 3133, C. bracarensis CNM-CL-7030 and C. bracarensis 153 MT). The opaque halo of 
degradation around the colonies grown on agar medium supplemented with (a) BSA, (b) egg and (c) sheep blood is visible. 
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This work showed that only a strain of C. bracarensis (NCYC 3133) is able to secrete 
protease (Pz=0.44), like C. tropicalis (Pz=0.44) and C. albicans (Pz=0.47). In relation to phospholytic 
activity, C. bracarensis strains were not able to produce phospholipases (Pz=1.00), like C. glabrata 
(Pz=1.00), contrarily to C. albicans (Pz=0.38). Nevertheless, all Candida species were able to express 
total haemolytic activity on sugar-enriched sheep blood medium, including C. bracarensis strains. 
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3.4. Discussion 
It is important to emphasize that, in general, significant differences (p<0.05) were detected in 
the virulence factors between C. bracarensis and C. albicans ATCC 90028 or C. glabrata 2001, and 
also among its different strains. Initially, C. bracarensis was misclassified as C. glabrata upon its 
discovery (4), and the results presented here highlight these differences, not only concerning species 
but even strains. In a case reported by Warren and colleagues (53), where two isolates of C. 
bracarensis were not initially classified as C. glabrata by the API 20C system, the misidentification 
already had been suggested. However, a detailed analysis of each virulence factors and a possible 
relationship between them, always having into account the different environmental conditions tested, 
will be now discussed. 
Adhesion is one of the first and important stages of biofilm formation (37). Investigations on 
adhesion ability of Candida species to plastic surfaces, such as polystyrene, and on the factors 
involved in this phenomenon have been reported before (97, 98). However, in the case of C. 
bracarensis, this ability is still unknown. For that reason, the present study proved that all C. 
bracarensis strains (NCYC 3133, CNM-CL-7030 and 153 MT) have the ability to adhere to polystyrene 
(Figure 3.1) like all pathogenic Candida species. 
Additionally, it was shown that the culture medium (YPD and RPMI) did not influence the 
number of viable adhered cells of C. bracarensis strains (Figure 3.1 (a)). The same was verified for C. 
glabrata, but not for C. albicans. The differences noted in the latter can be explained by the cells size 
grown in the YPD and RPMI. In fact, it was observed in Chapter 2 that the size of C. albicans cells in 
YPD was relatively smaller than in RPMI, while the cells of C. glabrata and C. bracarensis presented a 
constant size in both media. Moreover, some authors (97, 99) have corroborated this idea, 
considering the cells size as an important factor in the adhesion of Candida species to plastic 
surfaces.  
Contrarily to the observed in the CFUs results (Figure 3.1 (a)), the biomass values (Figure 3.1 
(b)) showed that the adhesion extension of all C. bracarensis strains was affected by the culture 
medium, i.e., there was a higher adhesion in RPMI medium than in YPD. Indeed, CFUs enumeration 
and CV staining are two complementary methods used to study the adhesion and biofilm ability 
formation, and effectively measure distinct data. CFUs enumeration provides the number of viable 
cells and CV method determine the total biomass values (viable, non-viable cells and the matrix 
present in biofilm) (93). This fact could justify the discrepancies observed between the two methods. 
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Concerning to RPMI medium, and through the biomass values, strains NCYC 3133 and 153 
MT showed a higher adhesion to polystyrene than the other Candida species. One possible 
explanation for that can be the cell wall surface proteins (e.g. adhesins). In fact, the fungal adhesins 
are proteins that have an important function in the interactions between the yeast cells and between 
the cells and the host tissues or inert surfaces (29, 30). In C. albicans and C. glabrata, the major 
group of these proteins is encoded by different genes families (ALS and EPA, respectively) (29, 100). 
In this sequence, small differences can be found between the adhesins of both species, influencing 
the adhesion process of each microorganism. In the case of C. bracarensis, there are no 
investigations about its adhesins so far. Nevertheless, and from the results obtained, there may be 
more efficient adhesins in the wall cell of C. bracarensis than in the other Candida species.  
Furthermore, the growth conditions can also influence the expression of the adhesins (10). In 
studies on the Epa proteins of C. glabrata (32, 33), it was observed that EPA genes are transcribed in 
the presence of nicotinic acid and that EPA6 expression was not detected in vitro, but in vivo during 
an urinary tract infection. In the case of C. albicans, it was demonstrated, for some strains, that ALS1 
gene is expressed in RPMI 1640, but not in YPD; and that its expression is not rigorously associated 
to hyphae formation. The presence of ALS3-specific signals was also verified in RPMI, but not in YPD 
(88, 101). These last observations suggested that expression of these two genes (ALS1 and ALS3) 
was induced by RPMI medium, which can justify the higher extension of adhered cells of C. 
bracarensis in RPMI than in YPD medium (assuming that all strains of C. bracarensis have Als 
proteins on their cell surfaces). 
Other factors, such as cell surface properties (e.g. hydrophobicity), could be indicated to 
explain the differences found between the studied species. Nonetheless, it is well known, that 
hydrophobicity is not a decisive factor in the adhesion process (35). There is not a consensus about 
the correlation between this property and the adhesion of Candida species to the surfaces. For 
example, in the previous studies developed by Panagoda et al. (34), a relationship between the 
adhesion of C. parapsilosis and the hydrophobicity of acrylic surfaces was verified. On the other hand, 
Silva et al. (36) observed that the hydrophilicity of some NCAC species (C. glabrata, C. parapsilosis 
and C. tropicalis) did not influence the adhesion of these strains. 
After the adhesion, it occurs the cell division, proliferation, and biofilm development (102). 
Thus, biofilm formation ability of C. bracarensis strains was also evaluated. Some authors (43, 103, 
104) have reported that Candida species (such as C. albicans and C. glabrata) form biofilms on 
abiotic surfaces (e.g. polystyrene), but concerning C. bracarensis there was no information available. 
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Thereby, this study was essential because it showed that C. bracarensis has the ability to form biofilm 
on polystyrene surfaces (Figure 3.2), an important phenomena that contributes for the survival and 
colonization of this species in host tissues and medical devices (43). 
 In addition, significant statistically differences were detected between biofilms formed for 24 
and 48 h for C. bracarensis (p<0.05), except for some situations. Nevertheless, these observations 
did not allow to establish a relationship between the incubation time and the extension of biofilm, 
although it is known that the complexity of these structures increases in function of time (105). 
Through simultaneous analysis of the number of viable cells and total biomass values (Figure 
3.2), it was observed that the culture media affected significantly (p<0.05) the formation of most part 
of C. bracarensis biofilms, like in the C. glabrata and C. albicans. These results match those of some 
authors (36, 106, 107), who reported that mature biofilms formation depends on specific 
environmental conditions, such as medium composition. Indeed, the different culture media can 
induce different alterations in the cells morphology and, consequently, in the biofilm characteristics 
(107). For example, in Chapter 2, it was demonstrated that C. albicans ATCC 90028 produces 
hyphae/pseudohyphae in RPMI, but not in YPD. In this sequence, the values of total biomass of this 
Candida species in both media were different (Figure 3.2 (c, d)) because CV method is sensitive to 
the presence or absence of these filamentous structures (108). 
Silva et al. (43) showed that, in a rich culture media, C. glabrata biofilms produce lower 
levels of biomass in comparison with the other NCAC species (specifically, C. tropicalis and C. 
parapsilosis). However, in the present case, all C. bracarensis biofilms presented lower total biomass 
values than C. glabrata biofilms (Figure 3.2 (c, d)). This observation was common in both culture 
media, with the exception of strain 153 MT in RPMI medium. Regarding C. albicans, some strains of 
this species have been reported as good biofilm producers in comparison to other Candida species 
(41, 42). In fact, this situation was also confirmed in this study, but only in RPMI medium (Figure 3.2 
(d)), where C. albicans biofilm had higher total biomass values than C. glabrata and all C. 
bracarensis biofilms. Concisely, these differences demonstrated that biofilm forming ability was highly 
species dependent. In similarity to what has been reported for other Candida species (such as C. 
albicans and C. parapsilosis) (43, 109), the biofilms formation of C. bracarensis showed to be also 
strain dependent, especially in RPMI, where the biofilms of strain NCYC 3133 presented the lowest 
total biomass values among C. bracarensis strains. 
Several authors (35, 36) have also reported a correlation between the adhesion and biofilm 
formation for C. albicans and NCAC species. With this work, it was also possible to verify, for all C. 
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bracarensis strains and in the RPMI medium, a relationship between these two phenomena: the 
strains that presented higher adhesion, in terms of biomass values (CNM-CL-7030 and 153 MT), were 
those that also showed the highest total biomass values after 24 and 48 h. 
 The presence and the composition of the ECM is also one important characteristic of biofilms 
(16, 38, 40). The biofilm matrix is composed by several products secreted by microbial cells and acts 
as a barrier to diffusion of antimicrobial agents, preventing, for that reason, the penetration and the 
access of drugs to cells located at the base of the biofilm (10, 38). Therefore, the protein and 
carbohydrates amounts present in the biofilms matrices formed by C. bracarensis strains were also 
quantified (Table 3.1). In the ECM composition values obtained, few significant differences between 
the 24 h and 48 h biofilms of C. bracarensis formed in YPD medium were observed (p<0.05). This 
fact did not allow us to establish a relationship between the time of biofilm formation and the matrix 
composition due to the few significant differences found. 
In what regards to the different culture media used, and in the similarity of biofilms 
formation, it was confirmed that the production of ECM is also dependent on growth medium, a fact 
already indicated by other authors (36, 38, 110). The differences between the two culture media were 
not so evident in the carbohydrates values, as in the proteins. In fact, the protein amount extracted 
from the biofilm matrices formed in YPD was significantly higher than in RPMI, regardless of the 
studied species or strain and of incubation time. Until the moment, there are no investigations 
focused in this fact, i.e., in the larger production of proteins in rich medium (YPD) than in poor 
medium (RPMI). However, it is possible to present a simple explanation for the phenomenon 
observed in the present work. As it is known, the glucose is a sugar that has been implicated in the 
synthesis of some proteins (30). As the YPD medium has a higher glucose concentration (in 
comparison to the RPMI medium), this induces a higher production of proteins. 
Moreover, it was also shown that C. bracarensis NCYC 3133 and C. glabrata were the only 
strains, which significantly presented more carbohydrates than proteins in their matrices of biofilm 
formed in RPMI and for 24 h and 48 h. This fact was also verified for C. bracarensis NCYC 153 MT, 
but only in the biofilm matrix formed for 24 h. Concerning the YPD medium, only the 24 h biofilms of 
C. bracarensis NCYC 3133 and C. albicans significantly (p<0.05) presented more carbohydrates than 
proteins in its matrices (p<0.01). The reverse situation, i.e., more proteins than carbohydrates, was 
also detected in some cases, but without significant statistically differences (p>0.05). Nevertheless, it 
is possible to refer that these results match those of Al-Fattani et al. (38), who reported that ECM of 
C. albicans biofilms contains a high level of carbohydrates and a low level of proteins. In an 
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investigation developed by Silva et al. (43), it was also revealed that biofilm matrices of C. glabrata 
are composed by high quantities of carbohydrates and proteins. 
 In this follow, differences in the protein amounts between the biofilm matrices formed by the 
three C. bracarensis strains were also detected in YPD medium. In this last medium, C. bracarensis 
CNM-CL-7030 was the strain that presented the highest proteins levels in the 24 h biofilm matrix. In 
the remaining conditions (including the carbohydrates results), there were not found significant 
differences between these strains (p>0.05). 
 Regarding the results obtained from biofilm formation and matrix composition, it was not 
possible to establish a correlation, in similarity to what was reported by Silva et al. (43) for NCAC 
species. This impossibility can be associated to the presence of other components in ECM, in 
addition to those that was analysed (proteins and carbohydrates). According to literature (38, 111), it 
is known that the biofilm matrix of Candida species can contain other substances, such as 
hexosamine, phosphorus and uronic acid. 
 Among the several virulence factors, the ability to secrete hydrolytic enzymes has also been 
demonstrated for C. albicans and other Candida species, but not for C. bracarensis (44, 45, 48, 49). 
These compounds play a major role in the pathogenicity of these microorganisms because they cause 
destruction of host tissues (5). Hence, the present work showed that only one strain of C. bracarensis 
(NCYC 3133) was able to secrete proteases, such as C. tropicalis and C. albicans (Figure 3.3). Negri 
et al. (44) demonstrated proteolytic activity in some C. tropicalis clinical isolates from hospitalized 
patients and Kumar et al. (45) detected that 83.6% of C. albicans isolates obtained from 
immunocompromised patients were capable of producing proteases. In the phospholytic activity, no 
strain of C. bracarensis produced extracellular phospholipases, like C. glabrata, but unlike C. 
albicans. Indeed, it has been shown that C. albicans has the ability to produce four types of 
phospholipases, but with respect to C. glabrata, there are no studies on this topic (5, 45). On the 
contrary, all strains of C. bracarensis expressed total haemolytic activity, like the other species (C. 
albicans, C. glabrata and C. tropicalis). In fact, the production of haemolysins has been verified both 
in C. albicans and NCAC species by several authors (44, 48, 49). 
 The enzymatic activity results (Figure 3.3) also proved that the production/secretion of 
proteases and phospholipases varied between the studied species and the C. bracarensis strains. The 
present obviousness had already been verified by other authors, such as Negri et al. (44). In addition, 
no correlation was observed between the hydrolytic enzymes production and the remaining virulence 
factors analysed in this current work. 
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 In summary, this study highlighted mainly the differences between the C. bracarensis strains 
and the C. glabrata (or C. albicans), in terms of virulence factors. In some situations (e.g. in values of 
adhesion and biofilm formation in RPMI medium), it was even verified that the C. bracarensis strains 
could be more pathogenic than the other species, so remitting for a new problematic question around 
the C. bracarensis resistance to antifungal agents. For that reason, the resistance to antifungal agents 
of this recent Candida species will be approached in the next section (Chapter 4). Moreover, 
differences among C. bracarensis strains were also constantly mentioned throughout this work. The 
explication for this fact can remain in the different sources from which the clinical isolates of C. 
bracarensis were obtained. In fact, in the human body, it is possible find focus with different 
ecological niches between them and, therefore, with different environmental conditions (43, 112). 
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4.1. Introduction 
Antifungal resistance is “the ability of a pathogen to continue to reproduce in the presence of 
an antifungal agent” (64). Unfortunately, this phenomenon has started to increase among Candida 
species in consequence of the increase of invasive fungal infections caused by the same 
microorganisms (61, 62). With the increase of these infections, antifungal agents are used 
excessively, contributing thus to the increase of resistant species and accumulation of mutations that 
cause resistance (6). Besides being a serious problem for human health, the antifungal resistance 
also creates economic problems (7). For that reason, it is urgent to understand the mechanisms 
involved in the Candidal resistance. 
The evaluation of the antifungal resistance is ordinarily performed by determination of the 
lowest agent concentration for which it is detected a significant reduction (50% or 90%) of the 
pathogen growth – the minimum inhibitory concentration (64, 113). Additionally, methods for 
susceptibility testing of Candida species have been standardized by the CLSI and EUCAST (63, 114). 
Broth macrodilution and microdilution, agar diffusion, disk diffusion and E-test are some of the 
techniques that have been proposed to test the antifungal susceptibility, i.e., to determine the MIC 
value of drugs against pathogen microorganisms (114). In this sense, several authors (62, 63, 71, 
76) have presented studies on the resistance of Candida species (mainly C. albicans), with the 
indication of the respective MICs values of the antifungal agents more commonly tested. 
Antifungal agents have cellular targets that, when affected by certain compounds, cause 
death or inhibition in the growth of pathogenic microorganisms. In some situations, Candida species 
are not affected by drugs’ action and, in these cases, the species are classified as resistant (5, 113). 
The majority of antifungal drugs, used in treatment of invasive Candida infections, has as major target 
the biosynthesis of ergosterol, an important sterol contained in the fungal cell membranes and 
involved in the membrane fluidity and cell division (6, 64). 
Concerning the resistance to antifungal drugs, several mechanisms, such as the decreased 
drug concentration in the site of action and the accumulation of the other sterols in the fungal cell 
membrane, have been presented. It is also important to refer that the emergence of these 
mechanisms is especially due to the occurrence of genetic mutations in the fungal pathogens (63, 
113). In the case of biofilms, that exhibit more resistance than planktonic cells, other factors have 
been implicated in the antifungal resistance: physiology, density, overexpressed targets, efflux pumps, 
ECM, persister cells and stress (71). 
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However, regarding C. bracarensis antifungal resistance, there is still lack of information. For 
that reason, the major aim of the study was to analyse the susceptibility of three strains of C. 
bracarensis to amphotericin B (fungicide) and to fluconazole (fungistatic), on both planktonic and 
sessile cells. The impact of these antifungal agents in the enzymatic activity of respective strains was 
also evaluated. 
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4.2. Materials and methods 
4.2.1. Organisms 
In this last part of the work, the same three C. bracarensis strains, C. albicans and C. 
glabrata were evaluated. The information about these Candida species is described in section 2.2.1. 
 
4.2.2. Planktonic cells susceptibility tests to antifungal agents 
In this experiment, the reference method described by the CLSI for broth dilution antifungal 
susceptibility testing of yeast (M27-A3) was used (115). 
The following antifungal agents’ concentrations, from 0.125 to 2 µg/ml for amphotericin B 
(Sigma) and from 2 to 1250 µg/ml for fluconazole (Sigma) were used to determine the MIC against 
the Candida strains under study. For that, 100 µl of antifungal and 100 µl of cell suspension in RPMI 
1640 (Sigma) medium, which density was adjusted to a turbidity of 0.5 McFarland standard (1 to 
5×106 cells/ml), were added to the selected wells. The 96-well plates (Orange Scientific, Braine-l’ 
Alleud, Belgium) were incubated at 37°C for 48 h. After the incubation, the number of viable cells 
was assessed by CFUs enumeration, which allowed to determinate the MICs of drugs. As described 
by CLSI M27-A3 (115), MICs were interpreted as follows: (i) amphotericin B: MIC>1 µg/ml – 
resistant; (ii) fluconazole: MIC≤8 µg/ml – susceptible; 16<MIC<32 µg/ml – susceptible-dose-
dependent and MIC≥64 µg/ml – R. These assays were repeated for three days, being individual 
samples analysed in triplicate. 
 
4.2.3. Biofilm cells susceptibility tests to antifungal agents 
In order to assess biofilm cells susceptibility to antifungal agents two approaches were taken: 
the antifungal agents were added simultaneously with cells for biofilm formation during 24 h (to 
mimic the prophylactic treatment) and antifungal agents were added, after 24 h, to pre-formed 
biofilms (to evaluate a therapeutic action). 
Several concentrations of the antifungal agents were prepared in RPMI 1640 medium: 0.5, 1 
and 2 µg/ml of amphotericin B and 50, 312.5 and 625 µg/ml of fluconazole. The strains were 
subcultured on YPD agar medium for 24 h at 37°C and afterwards cultured on YPD broth for 18 h at 
37°C. The yeast cells were harvested by centrifugation (at 3000 g for 10 min at 4°C), washed twice 
with PBS (pH 7.5, 0.1 M) and then suspended in RPMI 1640 (Sigma) to a final concentration of 
2.0×107 cells/ml. In order to adjust concentration, a Neubauer counting chamber was used. 
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On the prophylactic approach, 96-well polystyrene plates (Orange Scientific) were used and 
each well was filled with 100 µl of antifungal and 100 µl of the standardized cell suspensions. The 
plates were incubated at 37°C with 120 rpm for 24 h. In relation to the therapeutic approach, 100 µl 
of RPMI 1640 medium and 100 µl of the cell suspensions (2.0×107 cells/ml in RPMI 1640) were 
added to select wells, which were incubated at 37°C in an shaker (at 120 rpm). After 24 h, 200 µl of 
culture medium was removed and an equal volume of the respective antifungal concentration was 
added to the plates that were incubated for further 24 h. After each incubation time, the culture 
medium was aspirated and the wells were washed once with PBS (pH 7.5, 0.1 M). The results were 
assessed using CFUs enumeration method and by total biomass quantification (through CV staining), 
as described in Chapter 3 (3.2.3.1. and 3.2.3.2., respectively). All experiments were performed in 
triplicate and in four independent assays for each strain, antifungal concentration and approach. 
 
4.2.4. Effect of antifungal agents in the proteolytic, phospholytic 
and haemolytic activity production 
To evaluate the effect of the antifungal agents in the hydrolytic enzymes secretion, fresh 
colonies of each Candida strain were placed onto protease and phospholipase agar media (to 
proteases and phospholipases secretion, respectively) and inside of sugar-enriched sheep blood 
medium (to haemolysins secretion). Each specific agar media plates were supplemented with the 
respective antifungal agents’ concentrations: 0.25, 1 and 2 µg/ml of amphotericin B and 8, 16 and 
50 µg/ml of fluconazole. Subsequently, all plates were incubated at 37°C for 4 days (proteases) and 
3 days (phospholipases and haemolysins). Concerning to proteases assay, after incubation, the 
plates were placed in contact with 15 ml of dye solution, which composition was mentioned in the 
point 3.2.5. 1 h later, these Petri dishes were washed twice with acetic acid (33% v/v) and dried at 
room temperature. The proteolytic, phospholytic and haemolytic activity was assessed as described in 
the sections 3.2.5. and 3.2.6. 
 
4.2.5. Statistical analysis of data 
Statistical analysis was performed using GraphPad Prism software for Windows. The two-way 
ANOVA with the Bonferroni post-tests was used to compare the controls (0 µg/ml) with the resistance 
of strains (in the form planktonic and biofilm cells) to different concentrations of antifungal agent. All 
tests were performed with a 95% confidence level.  
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4.3. Results 
4.3.1. Candida bracarensis planktonic cells susceptibility to 
antifungal agents 
The levels of Candida strains susceptibility to amphotericin B and fluconazole, in the 
planktonic lifestyle, are presented in Figures 4.1 and 4.2, respectively. The results were interpreted 
according to the CLSI M27-A3 (115). 
 
 
Figure 4.1 - Number of viable cells of Candida strains in the presence of different concentrations of amphotericin B. Error bars represent standard 
deviation. Statistically different compared to respective control (*p<0.05; **p<0.01; ***p<0.001). 
 
 Concerning the amphotericin B (Figure 4.1), it was verified that the species C. bracarensis 
NCYC 3133 presented the highest resistance (1<MIC<1.5 µg/ml). In addition, it was also detected 
that the more susceptible strain was C. bracarensis 153 MT (0.25<MIC<0.5 µg/ml). Moreover, 
particularly in C. albicans (p<0.001), C. bracarensis NCYC 3133 (p<0.01) and C. bracarensis CNM-
CL-7030 (p<0.05), it was observed that 0.125 µg/ml of amphotericin B had statistically significant 
effect in the Candida death comparatively to the respective control. 
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Figure 4.2 - Number of viable cells of Candida strains in the presence of different concentrations of fluconazole. Error bars represent standard deviation. 
Statistically different compared to respective control (**p<0.01; ***p<0.001). 
 
The results of Figure 4.2 show that C. albicans ATCC 90028 (50<MIC<312.5 µg/ml) and C. 
glabrata ATCC 2001 (312.5<MIC<625 µg/ml) presented the highest resistant values to fluconazole. 
On the other hand, the three strains of C. bracarensis (NCYC 3133: 10<MIC<16 µg/ml; CNM-CL-
7030 and 153 MT: 16<MIC<25 µg/ml) could be classified as susceptible-dose-dependent, while C. 
bracarensis NCYC 3133 presented more susceptibility than the other strains. Furthermore, it was 
noted that fluconazole concentration of 2 µg/ml inhibited significantly the growth of all species under 
study, with the exception of C. glabrata (p<0.001). 
 
4.3.2. Candida bracarensis biofilm cells susceptibility to antifungal 
agents 
As already indicated in point 4.2.3., biofilm cells susceptibility to amphotericin B and 
fluconazole was analysed by two different approaches: the antifungal agents were added at the 
beginning of biofilm formation (to mimic the prophylactic treatment) or to pre-formed biofilms 
(mimicking the therapeutic approach). The results for each situation are presented afterwards. 
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4.3.2.1. During biofilm formation 
Figure 4.3 presents the number of viable cells and the total biomass resulting of Candida 
biofilm formation in the presence of amphotericin B and fluconazole. The first evidence observed in 
both figures was the inability of the fungicide (amphotericin B)/fungistatic (fluconazole) to kill/inhibit 
the growth of yeasts, within the range of concentrations tested. 
 
  
(a) (b) 
  
(c) (d) 
Figure 4.3 - (a, b) Number of viable cells of Candida species (c, d) and absorbance values of CV solutions per cm2 of biofilm in the presence of (a, c) 
amphotericin B and (b, d) fluconazole, during its formation. Error bars represent standard deviation. Statistically different compared to respective 
control (*p<0.05; **p<0.01; ***p<0.001). 
 
 Regarding amphotericin B, all tested concentrations allowed to reduce significantly (p<0.05) 
the formation of all studied biofilms: both in terms of viable cells number (Figure 4.3 (a)) and total 
biomass amount (Figure 4.3 (c)). Furthermore, it was not detected any significant differences 
(p>0.05) between the total biomass values of C. bracarensis NCYC 3133 biofilm in the presence (0.5 
µg/ml) and absence (control) of amphotericin B. However, this concentration (0.5 µg/ml) showed to 
be effective, principally, in preventing of biofilms formation of C. glabrata and C. bracarensis 153 MT. 
In the case of these two strains, the difference in relation to the respective control (0 µg/ml) was 
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quite significant (p<0.001), both in terms of number of viable cells and values of total biomass 
amount. Statistically significant difference (p<0.001) was also observed between the biomass of C. 
albicans biofilm in the presence of 0.5 µg/ml and the respective control. 
 Figure 4.3 (a) shows that, in the presence of concentrations of 1 and 2 µg/ml, biofilm 
formation of C. glabrata and C. bracarensis was reduced to over 33% in terms of the number of 
viable cells. Among these species, the lowest reduction was observed in the biofilm of the strain NCYC 
3133 (33.9% and 49.3% for each concentration, respectively). Moreover, the reduction of number of 
viable cells obtained during C. albicans biofilms’ formation did not exceed 33%. Figure 4.3 (c) 
demonstrates that the lowest reductions of the biomass were observed when C. bracarensis NCYC 
3133 biofilm were formed with 1 and 2 µg/ml, with a reduction of 41.8% and 62.5%, respectively. 
 Regarding fluconazole (Figure 4.3 (b, d)), it can be seen that this antifungal agent 
significantly inhibited the biofilm growth of all species (p<0.05), but with lower extension in the case 
of C. glabrata. In fact, only the concentration of 625 µg/ml was able to reduce significantly either in 
terms of viable cells (p<0.001) and total biomass (p<0.05). The concentration of 312.5 µg/ml was 
also significantly effective, but only at the level of the number of viable cells (p<0.001). For the other 
strains under study, the minimum concentration of fluconazole (50 µg/ml) used had a highly 
significant effect (p<0.001) in inhibiting the growth of its biofilms. This fact is proved by the reduction 
of the number of viable cells and total biomass quantification during biofilm growth, with the 
exception of biomass in C. bracarensis 153 MT biofilm. 
 In Figure 4.3 (b), it is also possible to observe that fluconazole acted in a similar way in the 
biofilms of the three strains of C. bracarensis. During C. bracarensis biofilms’ formation, the inhibition 
imposed by different fluconazole concentrations in the viable cells number was mostly higher than in 
the C. glabrata and C. albicans biofilms, where the inhibition did not exceed the 14.4% and 20.1%, 
respectively. Contrarily, and according to values from Figure 4.3 (d), the total biomass reduction in 
the C. bracarensis biofilms was lower than in the C. albicans biofilms, but remained higher than in 
the C. glabrata biofilms. In addition, among C. bracarensis species, the lowest biomass reduction 
happened in the biofilms of strain 153 MT (<28.5%), regardless of the tested fluconazole 
concentration. 
 
4.3.2.2. Pre-formed biofilms 
The number of viable cells and the total biomass values obtained after 24 h of contact 
between the antifungal agents (amphotericin B and fluconazole) and the pre-formed Candida biofilms 
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are represented in Figure 4.4. In this approach, the antifungal agents’ effect was effectively lower than 
that observed when the agent was added during biofilm formation. 
 
  
(a) (b) 
  
(c) (d) 
Figure 4.4 - (a, b) Number of viable cells of Candida species (c, d) and absorbance values of CV solutions per cm2 of biofilm in the presence of (a, c) 
amphotericin B and (b, d) fluconazole, after 24 h of growth. Error bars represent standard deviation. Statistically different compared to respective 
control (*p<0.05; **p<0.01; ***p<0.001). 
 
 The tested concentrations of amphotericin B were not able to destroy C. bracarensis NCYC 
3133 biofilms. In fact, no statistically significant differences (p>0.05) were found between the control 
and the tested conditions, either in terms of the number of viable cells number (Figure 4.4 (a)) or in 
the value of total biomass (Figure 4.4 (c)). 
In relation to the other strains, it was verified (Figure 4.4 (a)) that 0.5 µg/ml of amphotericin 
B had a statistically significant positive effect in the reduction of the number of viable cells of C. 
albicans (p<0.01) and C. bracarensis 153 MT (p<0.001) biofilms. However, the total biomass values 
(Figure 4.4 (c)) show that the amphotericin B only had a significantly positive effect (p<0.01) in the 
biofilm of these species at for values of concentrations higher than 1 µg/ml. Moreover, in the case of 
C. glabrata and C. bracarensis CNM-CL-7030 biofilms, a significant reduction (p<0.05) in the number 
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of viable cells was observed, despite only for concentrations of 1 and 2 µg/ml, whereas the biomass 
of these biofilms suffered a statistically significant decrease with 0.5 µg/ml (p<0.05) and 2 µg/ml 
(p<0.001), respectively. 
Regarding fluconazole, this antifungal agent had no effect on the number of viable cells in the 
C. bracarensis NCYC 3133 biofilm (p>0.05) comparatively to control (Figure 4.4 (b)). Nevertheless, in 
Figure 4.4 (d), it is possible to observe that the total biomass increased significantly in the presence 
of 625 µg/ml comparatively to control (p<0.01). The same happened for C. glabrata biofilm. The only 
difference was in the number of viable cells: they began to be significantly inhibited (p<0.05) from a 
concentration greater than 312.5 µg/ml. 
Figure 4.4 (b) also shows that the number of viable cells of C. albicans and C. bracarensis 
153 MT biofilms statistically decreased, however only for higher concentrations of fluconazole (625 
µg/ml). In contrast, and concerning total biomass values (Figure 4.4 (d)), it was observed that both 
strains presented opposite behaviours in relation to the fluconazole action. In fact, a concentration of 
50 µg/ml was able to reduce efficiently (p<0.001) the values of total biomass of C. albicans biofilms, 
in opposite what happens for C. bracarensis 153 MT biofilm. 
Moreover, fluconazole at the same concentration (50 µg/ml) was able to reduce the number 
of C. bracarensis CNM-CL-7030 biofilms (p<0.01) and its total biomass amount (p<0.05) 
comparatively to the control. However, it is important to note that fluconazole concentrations above 
50 µg/ml did not affect the total biomass amounts comparatively to the control. 
 
4.3.3. Effect of antifungal agents in the proteolytic, phospholytic 
and haemolytic activity production 
Table 4.1 shows the results of the antifungal agents’ effect in the enzymatic activity of 
Candida species. In this experiment, it was analysed if there was formation of an opaque halo of 
degradation around the colonies formed on specific agar medium in presence of amphotericin B or 
fluconazole. Thus, to evaluate if there was an increase in the halo size, in function of the tested 
concentration of antifungal agent, the Pz values were also calculated, particularly in the case of 
proteolytic and phospholytic activity. It is noted that these values were calculated and classified 
according to Price et al. (95): Pz=1.00 means that there is no enzymatic activity and Pz<1.00 
indicates the opposite. 
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Table 4.1 - Effect of amphotericin B (AMB) and fluconazole (FLU) on the enzymatic activity of the Candida species 
 
Conc. 
(µg/ml) 
Species 
C. tropicalis 
ATCC 750 
C. albicans 
ATCC 90028 
C. glabrata 
ATCC 2011 
C. bracarensis 
NCYC 3133 
C. bracarensis 
CNM-CL-7030 
C. bracarensis 
153 MT 
Pr
ot
eo
ly
tic
 A
ct
iv
ity
 
0 0.44 0.47 1.00 0.44 1.00 1.00 
AM
B
 
0.25 0.44  0.43  1.00 0.43  1.00 1.00 
1 0.44  0.44  1.00 0.44  1.00 1.00 
2 0.43  0.40  1.00 0.33  1.00 1.00 
FL
U
 
8 0.30  0.38  1.00 0.40  1.00 1.00 
16 0.29  0.42  1.00 0.45  1.00 1.00 
50 0.31  0.40  1.00 0.46  1.00 1.00 
Ph
os
ph
ol
yt
ic
 A
ct
iv
ity
 
0 1.00 0.38 1.00 1.00 1.00 1.00 
AM
B
 
0.25 1.00 0.38  1.00 1.00 1.00 1.00 
1 1.00 0.36  1.00 1.00 1.00 1.00 
2 1.00 0.40  1.00 1.00 1.00 1.00 
FL
U
 
8 1.00 0.36  1.00 1.00 1.00 1.00 
16 1.00 0.41  1.00 1.00 1.00 1.00 
50 1.00 0.40  1.00 1.00 1.00 1.00 
H
ae
m
ol
yt
ic
 A
ct
iv
ity
 
0 Total Total Total Total Total Total 
AM
B
 
0.25 Total Total Total Total Total Total 
1 Total Total Total Total Total Total 
2 Total Total Total Total Total Total 
FL
U
 
8 Total Total Total Total Total Total 
16 Total Total Total Total Total Total 
50 Total Total Total Total Total Total 
The Pz value decreased () or increased () 10% compared to respective control (0 µg/ml). 
The situations marked with symbol    refer to those where the reduction (or increase) did not exceed the 10% of control value. 
 
 In the proteolytic activity, it was confirmed that only strains of C. tropicalis, C. albicans and C. 
bracarensis NCYC 3133 secreted proteases. Table 4.1 shows that with the application of 2 µg/ml of 
amphotericin B, the Pz value of these strains (with exception of C. tropicalis) decreases comparatively 
to the respective controls. However, relevant changes were not detected in the Pz value between the 
control and the protease-producing strains when subject to 0.25 and 1 µg/ml of amphotericin B. 
Regarding the fluconazole effect, this antifungal agent also promoted the decrease of Pz value in all 
species and for all tested concentrations, except for the C.bracarensis NCYC 3133. In this last case, it 
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was verified that the alterations of Pz value did not exceed the 10% of the control value. In addition, in 
Table 4.2, it is possible to observe the differences of size of the opaque halo of degradation between 
the control and the different conditions tested. 
 
Table 4.2 - Effect of amphotericin B and fluconazole in secretion of proteases by Candida species (the opaque halo of degradation around the colonies 
grown on agar medium supplemented with only BSA (control) and with BSA and amphotericin B or fluconazole is visible) 
Species 
Concentration (µg/ml) 
0 
Amphotericin B Fluconazole 
0.25 1 2 8 16 50 
C. tropicalis ATCC 750 
       
C. albicans ATCC 90028 
       
C. bracarensis NCYC 3133 
       
 
 In what concerns phospholytic activity, the antifungal agents’ effect was only detected in C. 
albicans, the only species able to produce phospholipases among all Candida species under study. In 
this particular case, there was not an evident relationship between the Pz value and the action of 
amphotericin B and fluconazole, i.e., there were not differences higher to 10% between the control 
and the tested conditions. This situation was also verified in the case of haemolytic activity, where all 
Candida species caused total haemolysis on sugar-enriched sheep blood medium, regardless in the 
presence of the antifungal agents added. 
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4.4. Discussion 
Through a general analysis of the results obtained in this chapter, it was possible to verify 
that C. bracarensis strains presented different behaviours in the presence of amphotericin B and 
fluconazole, either in the form of planktonic cells, or in biofilm lifestyle. This first observation is 
associated to the different mechanisms of action of the two tested antifungal agents. Differences 
between C. bracarensis and C. albicans ATCC 90028 or C. glabrata ATCC 2001 were also observed 
for the same antifungal agent and on both planktonic and sessile cells. In some situations, C. 
bracarensis strains presented higher resistant than the other Candida species. Indeed, it has been 
demonstrated that the increase use of antifungal agents causes the emergence of new fungal species 
that exhibit a decreased susceptibility to these agents (76). For example, the empiric or prophylactic 
use of amphotericin B has been associated with the emergence of C. glabrata and C. lusitaniae 
(116), while the prophylactic use of fluconazole has been indicated as one of the causes for the 
emergence of C. glabrata and C. krusei (3). 
Concerning the susceptibility of planktonic cells to antifungal agents, which has been studied 
for the most well-known Candida species and by several authors (52, 106, 117, 118), the present 
work showed that all C. bracarensis strains presented different MICs for amphotericin B (Figure 4.1). 
While the strain NCYC 3133 was the most resistant species, C. bracarensis 153 MT presented the 
highest susceptibility, with a MIC between 0.25 and 0.5 µg/ml. Bishop et al. (52) had already 
demonstrated the susceptibility of the 153 MT to amphotericin B, being MIC=0.023 µg/ml1, although 
it has been used another technique for in vitro susceptibility testing. Moreover, it has been reported 
that the resistant Candida strains to amphotericin B often present a lower ergosterol amount than the 
more susceptible strains, due to the mode of action of this polyene (67, 69). In fact, amphotericin B 
is an agent that establishes a bind with ergosterol, within fungal membrane, causing porin channels 
formation and, consequently, alterations in the membrane permeability and cellular components 
leakage (65, 67). In this sense, and through the MICs obtained, it is possible to hypothesize that C. 
bracarensis NCYC 3133 possessed lower quantity of the ergosterol in its plasmatic membrane than 
the other strains analysed. On the other hand, 153 MT is the strain that, according to this theory, 
presented the highest quantity of ergosterol, followed by C. bracarensis CNM-CL-7030 that presented 
the same MIC of C. albicans and C. glabrata (0.5<MIC<1 µg/ml). It is necessary to refer that the MIC 
                                                 
1 It is important to refer that, in the study of Bishop et al., C. bracarensis 153 MT is mentioned as C. bracarensis TS. 
Although these designations are different, the strain is the same (as explained in point 1.3.1.1.). 
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of amphotericin B obtained for these last two Candida species are in agreement with previous 
investigations (62, 114, 117). 
These differences found in the susceptibility to amphotericin B are mainly associated to 
mutations in genes involved in the sterol formation (67, 69, 70). For example, a mutation in the 
ERG3 (gene involved in the ergosterol biosynthesis) causes deficiency in sterol ∆5,6-desaturase, 
leading to the formation and accumulation of other sterols and, consequently, to the resistance (61, 
69). Mutations in ERG11 and ERG6 genes may also generate resistance of Candida species to 
amphotericin B (5, 69, 70). 
Unlike what was observed for amphotericin B, the planktonic cells of the three C. bracarensis 
strains showed a similar behaviour in the presence of fluconazole (Figure 4.2), an agent that acts 
directly in the ergosterol pathway through the inhibition of a fungal enzyme (lanosterol 14α-
demethylase), resulting in the ergosterol depletion and in the accumulation of sterol precursors (e.g. 
lanosterol) (68, 69). All strains were classified as susceptible-dose-dependent, which allows the 
confirmation that these strains had not yet developed intrinsic resistance to this azole. Furthermore, 
in a previous study developed by Bishop et al. (52), C. bracarensis 153 MT presented a fluconazole 
MIC of 8 µg/ml, slightly lower than the obtained in this work (10<MIC<16 µg/ml), this difference can 
be justified by the use of different techniques in both studies. 
Moreover, the planktonic cells of C. bracarensis were more susceptible to fluconazole than 
the other Candida species. The resistance of C. glabrata to fluconazole, an agent which has been 
implicated in the emergence of this microorganism and in the incidence of infections caused by the 
same Candida species (3, 119), contrasted with the susceptibility presented by C. bracarensis to this 
azole. This fact reinforces the differences between these two species, demonstrating again that, in an 
initial phase, C. bracarensis was, in fact, misclassified as C. glabrata (4, 53). Additionally, it is also 
important to refer that the resistance of C. albicans or C. glabrata to fluconazole has been 
demonstrated by other authors (120-122). Mechanisms such as overexpression of specific drug efflux 
pumps, alteration in drug target, upregulation of target enzyme and alterations in sterol synthesis may 
be in the origin of this phenomenon (61, 63, 69). 
 Regarding the C. bracarensis biofilms (Figures 4.3 and 4.4), it was observed higher values of 
resistance to amphotericin B and fluconazole than the planktonic counterparts. The same was verified 
in the case of the other species under study. Indeed, Candida biofilms are generally 10-1000 times 
more resistant to antifungal agents than planktonic cells (16, 72). In the investigation of Hawser et al. 
(72), it was revealed, for the first time, that these agents (specifically amphotericin B and azoles) were 
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less effective against C. albicans biofilms, formed on small discs of catheter material, than against its 
planktonic cells. Subsequent studies (106, 117) indicated the same for biofilms of C. albicans and C. 
glabrata formed on surfaces of polystyrene. Nevertheless, in relation to C. bracarensis biofilms, there 
is still no investigation on its resistance to amphotericin B and fluconazole. 
 As previously mentioned, the susceptibility of C. bracarensis biofilm cells to amphotericin B 
and fluconazole was analysed by two approaches (before and during biofilm formation); and 
quantified by the CFUs enumeration and the CV staining. Although these two methods measure 
different data (93), in this study in particular, either the values obtained in both methods or in most 
of the conditions tested matched. 
Through simultaneous analysis of both approaches, it was verified that the antifungal 
resistance was higher in the pre-formed biofilms (Figure 4.4) than during its formation (Figure 4.3), 
regardless of the agent tested. In fact, the antifungal resistance of Candida species biofilms increases 
with the complexity of biofilm structure (105). The development of complex architectures restricts the 
penetration of drugs through the ECM, also hampering the access of these agents to cells deep in a 
biofilm (16, 123, 124). 
During C. bracarensis biofilms’ formation (prophylactic approach), and in what concerns to 
amphotericin B (Figure 4.3 (a, c)), the biofilms of strain NCYC 3133 presented the lowest 
susceptibility, while the C. bracarensis 153 MT biofilms were the most susceptible. The same was 
verified in the therapeutic approach (pre-formed biofilms) (Figure 4.4 (a, c)). In fact, these 
observations are in agreement with the results obtained for C. bracarensis planktonic cells 
susceptibility to amphotericin B (Figure 4.1), where the strains NCYC 3133 and 153 MT were 
considered the most resistant and susceptible species, respectively. The results obtained for both 
approaches highlight, once again, the possibility of the existence of differences in the amount, or 
composition, of the sterol present in the cell membrane of the different C. bracarensis strains (67). 
Comparing the C. bracarensis strains with the other species, similar susceptibilities to 
amphotericin B between the biofilms of strains 153 MT and C. glabrata were verified, when this agent 
was added at the beginning of the formation of these structures, and between the strains 153 MT and 
C. albicans, in their pre-formed biofilms. In this last approach, the low susceptibility of C. bracarensis 
CNM-CL-7030 was also similar to the biofilms of C. glabrata, which coincides with the results 
observed for planktonic cells (Figure 4.1), where these two strains had the same MIC. However, none 
of the tested concentrations of amphotericin B was able to eliminate all biofilm cells in both 
approaches. In previous investigation developed by Jain et al. (106), it was verified that the biofilms of 
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four isolates of C. glabrata presented MICs of amphotericin B higher or equal to 2 µg/ml, a value that 
corresponds to the maximum concentration used in this work. In case of the C. albicans biofilms, 
MICs of amphotericin B higher or equal to 2 µg/ml have been also reported (106, 125). 
 With regard to fluconazole, this agent interfered in the biofilm formation of all C. bracarensis 
strains practically in a similar manner (Figure 4.3 (b, d)), unlike to what was verified for amphotericin 
B (Figure 4.3 (a, c)). In this same approach, the susceptibility of C. bracarensis biofilms to this azole 
was higher than the observed in the biofilms of C. glabrata and C. albicans, at least in terms of viable 
cells number (Figure 4.3 (b)). The biomass values revealed the same comparison but only between 
the biofilms of C. bracarensis and C. glabrata (Figure 4.3 (d)). Indeed, in this present case, the 
biofilms’ formation of C. glabrata was resistance to some concentrations of fluconazole. Thus, it is 
possible to assume that there was a concordance between these observations and what was verified 
for susceptibility of the planktonic cells to fluconazole (Figure 4.2), because all C. bracarensis strains 
were considered the most susceptible to this agent, while C. glabrata showed a high resistance. 
  In the pre-formed biofilms (Figure 4.4 (b, d)), the strains NCYC 3133 and 153 MT presented 
less susceptibility to fluconazole, among the C. bracarensis strains. Comparatively to other Candida 
species, the biofilms of CNM-CL-7030 and C. albicans were the most susceptible to fluconazole in 
terms of the number of viable cells and values of total biomass amount, respectively. In the particular 
case C. bracarensis NCYC 3133 and C. glabrata, their biofilms presented a higher resistance to 
fluconazole, accompanied by a significant increase in total biomass values in the presence of 625 
µg/ml. This observation contradicts the high susceptibility demonstrated by planktonic cells of strain 
NCYC 3133 to fluconazole (Figure 4.2). In reality, no tested concentration of fluconazole showed to 
be able to inhibit the growth of all biofilm cells in both approaches, like amphotericin B. 
The increase of total biomass, observed in the biofilms of strains C. bracarensis NCYC 3133 
and C. glabrata, clearly indicates the presence of resistance mechanisms to fluconazole in the same 
structures. These mechanisms may also have been the cause of some of the situations mentioned 
above, particularly those where low susceptibilities to antifungal agents were observed for some 
biofilms. Although these mechanisms are not fully understood, there is a consensus in relation to 
some of them, specifically in the case of C. albicans biofilms (5). As regards C. glabrata biofilms, few 
studies have been performed so far and, as for C. bracarensis biofilms, there is no investigation 
available. However, some mechanisms detected in C. albicans biofilms have also been verified in 
biofilms formed by other Candida species (e.g. C. glabrata, C. krusei and C. parapsilosis), giving the 
idea that there are common mechanisms among the Candida species biofilms (71, 118). 
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Thus, one of mechanisms that can be in the origin of the phenomena previously mentioned 
is the overexpression of drug targets. In fact, in C. albicans biofilms exposed to fluconazole, it has 
been detected an upregulation of genes involved in ergosterol biosynthesis, which caused the 
production of several sterols and, consequently, the antifungal resistance (71). Moreover, persister 
cells, described as being “highly tolerant to antibiotics”, have been implicated in the biofilms’ 
resistance as well (74, 126). In some studies, the presence of these cells was verified in C. albicans, 
C. krusei and C. parapsilosis biofilms exposed to antifungal agents (such as amphotericin B) (71, 75). 
Another factor involved in the antifungal resistance of biofilms is the physiological stress. This stress 
causes mutations in proteins that interfere in biofilm formation and, consequently, the resistance 
(71). For example, in the case of C. glabrata biofilms, upregulated proteins have been associated to 
stress responses (118). Efflux pumps, which are differentially expressed during biofilm formation, 
have also been reported in the antifungal resistance of Candida biofilms in the early phase of their 
development, but not in the following stages (73). In addition to these, other mechanisms of 
antifungal resistance have been indicated for Candida biofilms: its decreasing metabolic activity and 
its high anti-oxidative capacities (118). 
 ECM has been referred as an important mechanism in the antifungal resistance of biofilms 
because it functions as a protective barrier of cells embedded in it, by hampering the diffusion of 
antifungal agents (71, 73). Nevertheless, and through the results obtained for ECM composition of 
strains under study (presents in the Chapter 3), no correlation was found between the matrix 
composition and the antifungal resistance of biofilms, with exception of C. glabrata. Indeed, the 
highest carbohydrates amount was detected in the biofilm matrices of C. glabrata, the same species 
that, along with C. bracarensis NCYC 3133, presented the most resistant biofilms to fluconazole. The 
absence of a relationship between these two concepts for other Candida species (or tested 
conditions) is also not unusual. In an investigation performed by Baillie et al. (111), it was 
demonstrated that there is not a relationship between the extent of matrix formation and the 
resistance of C. albicans biofilms to antifungal agents. Furthermore, and knowing that C. albicans is 
the only strain under study that produces hyphae or pseudohyphae in RPMI medium (as shown in 
Chapter 2), the architecture of C. albicans biofilms contrasts with the one of other biofilms that are 
composed essentially by cells. This characteristic did not have much influence in the antifungal 
resistance process because there were situations where the strains, which do not produce hyphae, 
developed biofilms more resistant than C. albicans. This evidence agrees with the one indicated by 
Seneviratne et al. (118). 
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Changes in antifungal susceptibility and in virulence factors of Candida species have been 
found due to an extensive use of antifungal agents (127, 128). In this sense, the effect of these 
agents in the enzymatic activity of Candida species, an important virulence factor involved in the 
pathogenesis of invasive candidiasis (5, 49), was also under analysis. As there are few studies on this 
topic, with regard to C. bracarensis, there is no information available. However, in an investigation 
developed by Negri et al. (49), the influence of amphotericin B and fluconazole in the enzymatic 
activity of Candida species cells was shown. The same was verified in this work (Tables 4.1 and 4.2), 
but only in the proteolytic activity and for some Candida species. In case of phospholytic and 
haemolytic activities, no significant influence of antifungal agents was detected, regardless to the 
added concentration. Concerning these two enzymatic activities, it was possible to prove that C. 
albicans was the only strain able to produce phospholipases, while the haemolysins were produced 
by all Candida species, as it had already been verified in Chapter 3. It is also important to refer that 
the production of phospholipases in C. albicans and the presence of haemolytic activity in C. albicans 
and NCAC species have been reported by some authors (44, 45, 48, 49). 
 Regarding the proteolytic activity, C. bracarensis NCYC 3133 was the only strain that 
produced proteases, as well as C. tropicalis and C. albicans, but unlike C. glabrata. The results 
obtained for these three last species are agreed with those described in the literature (44, 45). 
Furthermore, the application of 2 µg/ml of amphotericin B caused an increase in proteolytic activity 
of C. albicans and C. bracarensis NCYC 3133, which can be related with the decrease of Pz value2 
compared to control. This increase on value of proteinase can be justified by the mechanism of action 
of amphotericin B. In fact, with the porin channels formation in the cell membrane,  the leakage of 
cellular components, such as proteases (enzymes that cause the destruction of host tissues) occurs 
(65, 67). The present study showed also that amphotericin B promoted the segregation of proteases, 
suggesting that this antifungal agent can be toxic for the human organism. The toxicity of 
amphotericin B has also been indicated in some studies (65, 68). Additionally, and with respect to 
strain NCYC 3133, there is a relation between these observations and the results obtained for the 
susceptibility of its planktonic cells (Figure 4.1). The resistance demonstrated by the planktonic cells 
of C. bracarensis NCYC 3133 to amphotericin B can be related to the proteases production by the 
same strain. In what concerns proteolytic activity of C. albicans ATCC 90028, it is relevant to mention 
that its increase caused in presence of amphotericin B has already been reported by Negri et al. (49). 
                                                 
2 There is enzymatic activity when Pz<1.00. Within this range of values, small Pz values mean more enzymatic activity and 
vice-versa. 
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 The fluconazole also affected the proteases production, but only in the C. tropicalis and C. 
albicans species. All tested concentrations of this agent promoted a significant increase of proteolytic 
activity of these strains, as result of the decrease Pz value compared to the respective control. In the 
case of C. albicans, this result agrees with those described by Negri et al. (49). In this last 
investigation, where C. albicans ATCC 90028 cells have grown in the presence of 64 µg/ml of 
fluconazole, proteolytic activity increased in comparison to control. In relation to C. tropicalis, the 
study of Negri et al. (49) showed the opposite of what was verified in this work. 
 In conclusion, the present study emphasizes the differences in antifungal resistance between 
C. bracarensis and C. albicans ATCC 90028 or C. glabrata 2001, and also among its different strains. 
For example, C. bracarensis NCYC 3133 showed to be the most resistant strain, mainly to 
amphotericin B. These different susceptibilities found between the strains of the same species are 
also related with the different infections/diseases from which the clinical isolates of C. bracarensis 
were obtained (44). Moreover, the cause of antifungal resistance, observed in some situations for C. 
bracarensis, can be due to genetic mutations (that lead mainly to resistance of planktonic cells) and 
several factors such as physical structure, cell density, biofilm matrix, overexpression of drug targets, 
persister cells, stress or efflux pumps (that, altogether with the genetic mutations, cause resistance to 
biofilm cells) (71). Therefore, new antifungal agents with new targets should be developed, taking in 
account these resistance mechanisms. 
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5.1. Concluding remarks 
In the present work, three strains of C. bracarensis (NCYC 3133, CNM-CL-7030 and 153 MT) 
were studied in terms of its general characteristics, virulence factors and antifungal resistance. This 
new Candida species, recently discovered through an epidemiological study of candidiasis (in the 
north of Portugal), was initially identified as C. glabrata. For that reason, comparisons between these 
two species were performed, as well as between C. bracarensis and C. albicans, which is the species 
of genus Candida more studied. 
Concerning general characteristics of C. bracarensis, all strains presented white colonies on 
chromogenic agar medium, unlike C. albicans and C. glabrata. In YPD, RPMI and hyphae inductor 
medium, strains NCYC 3133 and CNM-CL-7030 formed elliptical cells, such as C. albicans, while C. 
bracarensis 153 MT produced cells with an oval shape, in similarity to C. glabrata. Additionally, it was 
verified that the cells of all C. bracarensis tested presented an intermediate size, comparatively to the 
other Candida species, and were unable to form filamentous structures. In terms of the growth 
kinetics, all C. bracarensis strains had a behaviour similar to C. albicans and C. glabrata, although 
differences between the respective specific growth rates have been found. 
In respect of the virulence factors, C. bracarensis showed to be able to adhere, forming 
biofilm and producing ECM on polystyrene. In the case of adhesion, strains CNM-CL-7030 and 153 
MT presented a higher extension in RPMI than the other studied species, while in the biofilm 
formation, all C. bracarensis strains showed lower total biomass values than the biofilms formed by 
C. glabrata (in most of the conditions tested) and C. albicans (only in RPMI medium). In addition, the 
NCYC 3133 biofilms presented the lowest total biomass values among C. bracarensis strains, in RPMI 
medium. Regarding the composition of the ECM, few differences were found between the studied 
species under the same experimental conditions. Moreover, it was also showed that like C. albicans, 
but contrarily to C. glabrata, C. bracarensis NCYC 3133 was able to secrete proteases. All C. 
bracarensis tested were also able to cause total haemolysis, but were not able to produce detectable 
phospholipases. 
 In the analysis of C. bracarensis resistance to antifungal agents, it was verified that this 
Candida species presented higher resistance to amphotericin B than to fluconazole, comparatively to 
the other studied species. The strain NCYC 3133 proved to be the most resistant species to 
amphotericin B, both in planktonic cells and in biofilm, while C. bracarensis 153 MT showed the 
highest susceptibility. On the other hand, all C. bracarensis strains presented higher susceptibility to 
fluconazole than the other Candida species, specifically in terms of planktonic cells. Furthermore, and 
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in similarity to C. albicans or C. glabrata, the C. bracarensis biofilms were more resistant to 
amphotericin B and fluconazole than its counterpart’s planktonic cells. In the two approaches used to 
analyse the biofilm cells susceptibility, it was also observed a higher resistance in the pre-formed 
biofilms than during its formation, regardless of the agent tested. In relation to the effect of these 
agents in the enzymatic activity of the studied species, it was verified that amphotericin B caused a 
significant increase of proteolytic activity of C. albicans and C. bracarensis NCYC 3133, while the 
fluconazole promoted the proteases production in the C. albicans and C. tropicalis. 
 In general, this work emphasized the differences between C. bracarensis and C. glabrata (or 
C. albicans) and also among its different strains. However, typical phenotypic characteristics of 
Candida group were also identified for C. bracarensis, proving so that this fungus belongs, in fact, to 
genus Candida. 
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5.2. Future perspectives 
As already previously referred, C. bracarensis is a new pathogenic Candida species and, for 
that reason, there are few studies about it so far, specifically in terms of virulence factors or antifungal 
resistance of sessile cells. In this sense, there is still much to discover about this microorganism. 
However, and taking into account the results obtained in this work, it is possible to provide 
some suggestions for future investigations: 
 
i. It was mentioned that the differences found in the adhesion of different strains to 
polystyrene (in RPMI medium) could be associated to the presence of specific cell wall 
surface proteins, such as adhesins. In this sequence, it would be interesting to study the 
type of adhesins contained in C. bracarensis cell wall, as well as the conditions, which 
potentiate the differences in expression. This characterization could be performed through 
a proteomic analysis. 
 
ii. In the study of enzymatic activity, it was verified that all C. bracarensis strains secreted 
haemolysins and that the species NCYC 3133 was able to produce proteases. Thus, the 
identification and characterization of haemolysins and proteases encoded by these strains 
could be another object of study. 
 
iii. Some C. bracarensis strains showed resistance to amphotericin B and fluconazole 
(specifically the strain NCYC 3133), either in the form of planktonic cells or in biofilm 
lifestyle. Therefore, it is suggested the recognition of resistance mechanisms and of genes 
involved in this phenomenon in the development of new therapies with new potential 
targets. 
 
iv. Another recent species has been reported together with C. bracarensis – C. nivariensis 
(56-59). This last strain was also originally identified as C. glabrata, in similarity to C. 
bracarensis (52). For that reason, it would be interesting to compare C. nivariensis with C. 
bracarensis. 
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Appendix A – Calibration curves 
 Calibration curves were performed to protein and carbohydrate quantification. In Figure A.1 it 
is represented the relationship between concentration (µg/ml) of one protein (BSA) and optical 
density (562 nm). 
 
 
Figure A.1 - Calibration curve of BSA. 
 
 Calibration curve of glucose (Figure A.2) reflect the relationship between glucose 
concentration (mg/ml) and optical density (490 nm). 
 
 
Figure A.2 - Calibration curve of glucose. 
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